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 The goal of this research was to determine the effect of different doses of 
galactooligosaccharide (GOS) on the fecal microbiota of healthy adults, with a 
focus on bifidobacteria.  The study was designed as a single-blinded study, with 
eighteen subjects consuming GOS-containing chocolate chews at four increasing 
dosage levels; 0, 2.5, 5.0, and 10.0 g.  Subjects consumed each dose for 3 
weeks, with a two-week baseline period preceding the study and a two-week 
washout period at the end.  Cultural methods were used for bifidobacteria, 
Bacteroides, enterobacteria, enterococci, lactobacilli, and total anaerobes; 
culture-independent methods included denaturing gradient gel electrophoresis 
(DGGE) and quantitative real-time PCR (qRT-PCR) using Bifidobacterium-
specific primers.  All three methods revealed an increase in bifidobacteria 
populations, as the GOS dosage increased to 5 or 10 g.  Enumeration of 
bifidobacteria by qRT-PCR showed a high inter-subject variation in bifidogenic 
effect and indicated a subset of 9 GOS responders among the eighteen subjects.  
There were no differences, however, in the initial levels of bifidobacteria between 
 
the responding individuals and the non-responding individuals.  In order to gain a 
community wide perspective of the impact of GOS on the fecal microbiota of the 
subjects, we then performed high throughput multiplex community sequencing of 
16S rRNA tags.  Multiplex sequencing of the 16s rRNA tags revealed that GOS 
induced significant compositional alterations in the fecal microbial populations by 
increasing the phyla Actinobacteria.  The population shifts caused by 
consumption of 10 g of GOS were numerically substantial, leading for example, 
to a ten-fold increase in bifidobacteria in four subjects, enriching them to 18-33% 
off the fecal microbial community, and a five-fold increase in seven additional 
subjects.  This increase in bifidobacteria abundance was generally at the 
expense of only one group of bacteria, namely the genus Bacteroides.  
Collectively, this study showed that a high purity GOS, administered in a 
confection product at doses of 5 g or higher, was bifidogenic, while a dose of 2.5 
gram showed no significant effect.  Our results also demonstrated that GOS is 
remarkable for its ability to enrich specifically for bifidobacteria in human fecal 
samples. 
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Preface 
This thesis is composed of four chapters.  Chapter 1 provides a review of 
the current literature on the effects of prebiotics on the human intestinal 
microbiota, with a special focus on galactooligosaccharides (GOS).  Chapter 2 
describes our published (Davis et al., 2010 Int. J. Food Microbiol. In press) 
results focusing on the impact that consecutive doses of the prebiotic 
galactooligosaccharides have on the intestinal microbiota of healthy adults.  
Chapter 3 describes additional results from that study, where we focus on 
community sequencing and the highly specific bifidogenic response GOS has on 
the human gastrointestinal tract.  Finally, Chapter 4 provides a conclusion section 
that summarizes the major research findings presented within this thesis and the 
suggested areas for future research. 
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Prebiotic Activity of Galactooligosaccharides: 
A Review of structure, function, and in vivo human studies 
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Introduction 
Consumers have become increasingly aware of the importance of the 
human gastrointestinal microbiota in promoting health and well-being (48, 55).  
However, because the human intestine is a complex ecosystem in which 
thousands of different bacterial species reside, defining the microbial composition 
and establishing the function of this ecosystem represent a considerable 
challenge.  Nonetheless, there is now substantial interest in understanding the 
role of the colonic microbiota and developing the means to manipulate the 
composition of the intestinal microbiota to enhance human health (30).  In 
particular, the role of diet has been the subject of much of this interest, due to the 
potential impact specific dietary substances may have on the intestinal 
environment. 
Without doubt, the group of dietary substances that have received the 
most attention for their ability to modulate the colonic microbiota are the 
prebiotics.  Prebiotics are defined as a “a selectively fermented ingredient that 
allows specific changes, both in the composition and/or activity in the 
gastrointestinal microbiota that confers benefits upon host welling-being and 
health” (52).  Most of the compounds currently recognized as prebiotics are 
carbohydrates, either polysaccharides or oligosaccharides.  Although many 
carbohydrates have been suggested to have prebiotic activity (31), the most well-
studied include the fructans, inulin, and fructooligosaccharides (FOS), and the 
galactooligosccharides (GOS).  The latter are of particular interest due to their 
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similarity to human milk oligosaccharides.  Moreover, the ability of GOS to enrich 
for bifidobacteria and/or lactobacilli in the human intestinal tract is now well-
established.  However, many questions remain regarding the amount of GOS 
necessary to generate bifidogenic (or lactobacilligenic) changes in the human 
intestinal tract, the means of delivery and stability of GOS in foods, and the effect 
of GOS on the overall composition of the microbiota. 
In this review, the classification, structure, and means of production of 
prebiotics, and GOS in particular, will be described.  An overview of intestinal 
microbial ecology will also be described, including how prebiotics and GOS 
influence the microbiota.  Finally, published results using GOS in human feeding 
trials, including studies with infants, healthy adults, and elderly adults will be 
reviewed.   
 
Classification and Properties of Prebiotics 
The recent commercialization of non-digestible oligosaccharides as food 
ingredients has triggered a vast amount of research on their potential role in 
colonic health.    Since these non-digestible oligosaccharides are not hydrolyzed 
by enzymes in the human small intestine, they reach the colon almost intact, and 
have coined the name “prebiotics” (3).  Prebiotics were first defined as a „non-
digestible food ingredient that beneficially affects the host by selectively 
stimulating the growth and/or activity of one or a limited number of bacteria in the 
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colon, and thus improves host health‟ (30).  This prebiotic definition has since 
then been revised to „a selectively fermented ingredient that allows specific 
changes, both in the composition and/or activity in the gastrointestinal microbiota 
that confers benefits upon host welling-being and health‟ (53).  Many food 
oligosaccharides and polysaccharides have claimed to provide prebiotic activity 
(including dietary fiber), however, not all dietary carbohydrates are considered 
prebiotics.  Those classified as prebiotics are short-chain oligosaccharides and 
the degree of polymerization of these oligosaccharides varies from 2 to 60. (16, 
64; Table 1).  Based on this and other potential claims to follow, there is a need 
to establish clear criteria for classifying a prebiotic.  These classifications require 
that the ingredient demonstrates (i) resistance to hydrolysis and absorption in the 
upper part of the gastrointestinal tract; (ii) serve as a selective substrate for 
fermentation by one or a limited number of potentially beneficial bacteria in the 
colon, resulting in an increase in their growth and/or metabolic activity; (iii) alter 
the composition of the colonic microflora toward a healthier composition, and (iv) 
encourage effects that are beneficial to the host‟s health(24, 30, 70, 71).  While 
the research on prebiotics is continuing to surge, most of the studies involving 
prebiotic oligosaccharides have been carried out using inulin and its 
fructooligosaccharide (FOS) derivatives, together with various forms of 
galactooligosaccharides (GOS).  Specifically, inulin and FOS have been studied 
intensively in vivo over the past decade, while the studies associated with GOS 
are still young but hold potentially promising data for the prebiotic field. 
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Table 1. Carbohydrates used as prebiotics1 
Fructooligosaccharides (FOS) 
Galactooligosaccharides (GOS) 
Gentiooligosaccharides 
Inulin 
Isomaltooligosaccharides 
Lactulose 
Lactosucrose 
Soybean oligosaccharides 
Xylooligosaccharides 
__________________________________ 
1 Adapted from (67, 68) 
  
Galactooligosaccharides (GOS) 
Human Milk Oligosaccharides – GOS.  For the first few months of life, human 
milk is often the sole dietary source.  Not only does it contain all the nutrients 
necessary for infants to thrive, but also nutrients that may provide health benefits 
beyond those of traditional nutrients, such as GOS.  Human milk is considered 
one of the earliest sources of GOS with approximately 7% carbohydrates, 90% of 
which is lactose, and a variety of oligosaccharides based on lactose (21, 57).  
Oligosaccharides, after lactose and lipids, make up the third largest component 
in human milk (61), and are found at their highest levels in colostrum, where they 
can reach up to 24% of the total colostrum carbohydrates.  In the first two months 
after birth, the concentrations of these oligosaccharides steadily decrease to 
between 19% and 15% (57).  Human milk oligosaccharides, once ingested, can 
withstand the low pH in the gut (32) and resist degradation through enzymes 
from the pancreas and brush border membrane (20, 32).  Once these human 
milk oligosaccharides reach the gastrointestinal tract, they have been shown to 
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establish a microbiota predominant in lactobacilli and bifidobacteria (45), which 
differs from that of infants fed on cow‟s milk (37, 51).  Oligosaccharides in milk 
can reach as high as 8-12 g l-1 (46, 47), which is 100 times greater than in cow‟s 
milk.  The ability of breast-fed infants to utilize oligosaccharides in breast milk, 
including GOS which infants cannot digest in the upper gut, is thought to be the 
reason for the predominance of bifidobacteria within the gastrointestinal 
microflora (20, 37, 62).  When human milk is not available for various reasons, 
incorporation of manufactured prebiotics such as GOS can be a useful addition 
to formulas so that functional characteristics associated with breast milk can be 
replicated, such as its bifidogenic effects (52).  A mixture can be developed for 
formula that is based on the analysis of human milk and the high concentration of 
galactose.  These formulas can later be fed to infants to obtain comparisons of 
gut microbiota and fecal fermentation product composition to determine the 
closeness of relation to that of breast-fed infants (see later).   
Composition and properties of GOS.  There are three main methods by which 
prebiotic oligosaccharides are produced: (i) plant extraction of natural 
oligosaccharides, (ii) monitored hydrolysis of natural polysaccharides, and (iii) 
using hydrolases and/or glycosyl transferases from microbial or plant sources for 
enzymatic synthesis (34, 49).  The final structure composition of the prebiotic is 
dependent on the method in which the prebiotic is produced.  Linkages that are 
recalcitrant to hydrolysis by human or microbial hydrolases, such as β-glycosidic 
linkages, are generally found in all prebiotics (72).  GOS are produced from 
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lactose through the action of β-galactosidases, and, depending on the source of 
the β-galactosidase, different synthetic product mixtures are formed (19).  In 
general, β-galactosidase is known as an enzyme that is able to catalyze the 
hydrolysis of lactose, while also being able to catalyze the transgalactosylation 
reaction needed to develop the GOS product (28, 65).  It is thought that 
increased specificity of GOS can be obtained by using β-GOS, which is 
synthesized by bifidobacteria, utilizing their own β-galactosidase in the 
manufacturing of the product.  GOS consists of chains of galactose molecules 
ending in a terminal glucose molecule, with a degree of polymerization (DP) from 
between 2 to 10 and various types of linkages.  Production of GOS for 
commercial products utilizes whey-derived lactose as the main raw material (4, 
102), however GOS can be produced from lactose in cow‟s milk.  Since whey is 
produced in large amounts by the dairy industry as a by-product of cheese 
making, it becomes a more efficient way of reducing waste (52).  When in syrup 
form, GOS is usually transparent and more viscous than high-fructose corn 
syrups (HFCS).  When compared to sucrose, GOS has about one third of the 
sweetness (63), and shows a good moisture retention and high solubility (52).   
 
 
Figure 1. Synthesis of galactooligosaccharides from lactose refined from whey1.  
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1Adapted from (52) 
GOS Stability in Foods.  As effective functional food ingredients, prebiotics 
must be chemically stable to food processing conditions.  Many processing 
treatments involve low pH or heat, such as yogurt fermentation or pasteurization, 
which may hydrolyze the prebiotics to their respective monosaccharides.  In 
addition, some prebiotic structures consist of reducing ends, which through 
Maillard reactions may interact with amino acids present in proteins.  
Hydrolyzation of prebiotics would not allow them to retain prebiotic activity in 
vivo, due to the released monosaccharides being absorbed in the intestinal tract.  
This would allow the prebiotics to be utilized by the general commensal 
microflora, instead of selecting for beneficial intestinal and/or prebiotic bacteria in 
the colon.  Maillard reactions may also reduce the prebiotic activity and make 
them no longer available for metabolism by beneficial bacteria.  The chemical 
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stability of GOS was reported in a study performed by Sako et al (1999).  Using 
aqueous buffered solutions of Oligomate 55, stability was observed at 100˚C and 
pH 2, 120˚C and pH3, and at 160˚C and neutral pH.  When compared to sucrose 
at 10% concentration, GOS was found to be about three times more stable, as 
sucrose was degraded under many of the conditions tested.  GOS was also 
found to be stable when tested in acidic conditions during long-term storage at 
room temperature.  Due to their stability, GOS can be incorporated into a wide 
variety of foods (in some cases coupled with FOS) and are currently used in 
commercial commodities including infant formulas, dairy products, sauces, 
soups, breakfast cereals, beverages, snack bars, ice creams, bakery products, 
animal feeds, and as sugar replacements (103). 
Health benefits linked to GOS.  The human gastrointestinal tract, especially the 
colon, is a somewhat recently explored microbial ecosystem, offering a good 
opportunity for the development of dietary interventions targeting disease 
reduction risk and maintenance of good health.  Since GOS has been shown to 
be fermented by the colonic bacterial flora, in particular bifidobacteria, studies 
investigating the potential bifidogenic relationship are ever growing.  The 
bifidobacteria population is not only important for the eco-physiology of the 
colonic microbiota; they are also believed to have health benefits.  Evidence has 
shown that bifidobacteria are the main species colonizing the infant 
gastrointestinal microbiota, which in turn has decreased the overall numbers of 
potentially pathogenic bacteria.  However, with age, the number of bifidobacteria 
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begins to decrease and is slowly replaced by bacteria mainly associated within 
the phylum Firmicutes or Bacteroidetes.  Due to this decrease, efforts to restore 
or increase this population through the use of prebiotics, especially GOS, has 
become of great interest.  These organisms have been linked to increased 
resistance to infection and diarrheal disease (33, 74, 93, 101), stimulation of 
immune system activity (44, 77), as well as protection against cancer (69, 78).  In 
animal models, some bifidobacteria manifest strong anti-mutagenic and anti-
tumor properties that have prophylactic and therapeutic benefits (39).  Along with 
potential immune benefits, GOS has been studied as a potential therapeutic 
agent for IBS and IBD patients, by fermenting and increasing bifidobacteria that 
demonstrate pro-inflammatory like benefits and improve abdominal symptoms 
(82).  GOS has also been linked to potential laxative-like properties within elderly 
by relieving constipation, however, responses differ individually (89).  Small 
human trials, with mixed effects, involving GOS and the potential to stimulate true 
calcium absorption in postmenopausal women have also been performed.  An 
increase in calcium absorption in postmenopausal women was observed, 
however further research is required for any definitive conclusions to be drawn 
(97).  GOS has been under investigation in the area of cardiovascular effects as 
well, and very few trials have used it as a prebiotic.  In a study performed by van 
Dokkum and colleagues (1999), GOS did not seem to alter blood lipid 
concentration and glucose absorption; however it should not be excluded for 
people with elevated blood lipid concentration or diabetic patients, where it 
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potentially could be beneficial.  Another area of interest, with respect to prebiotic 
benefits, is allergic disorders.  The prevalence of allergic disorders in developed 
countries has been on a steady increase over the last few decades.  A delayed 
maturation of the immune system has been associated with a higher risk of 
allergies in children, and it has been suggested that breast feeding reduces this 
incidence.  Since breast feeding is associated with high levels of GOS, 
supplementation of GOS has been shown to induce a beneficial antibody profile 
in infants at risk for allergy, while leaving the response to vaccination intact (99).   
Given that positive results have arisen from animal studies, it is important 
that systematic studies are continually instigated to test for continued GOS 
benefits in humans.  Researchers are probably just beginning to touch the full 
potential of health benefits conferred by GOS and so far, the majority of 
investigations have focused on more obvious gastrointestinal-related diseases.  
Other areas of health, however, will undoubtedly expand on these potential 
benefits in the future.   
The Human Intestinal Microbiota 
This predominantly anaerobic microbiota is able to salvage energy for the 
host by fermenting undigested carbohydrates and proteins to short-chain fatty 
acids, which are then absorbed (15).  The intestinal microbiota may also 
synthesize vitamins (18), protect against invasive species that are often 
pathogenic (10, 26), and possibly contribute to the economy of essential amino 
acids in humans (85, 94).   
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Breakdown of polysaccharides in the large intestine is a complex process 
involving various enzymes (poly-, oligo- and monosaccharidases) from many 
different species, and cross-feeding by the microflora (15).  Evidently the effect of 
such a process on the growth of specific bacteria is difficult to predict in an 
ecosystem consisting of such a large number of physiologically and nutritionally 
diverse bacterial species.  Not all intestinal bacteria are beneficial to health, and 
a long-established concept is that of beneficial and possibly harmful species.  
Generally beneficial genera include Bifidobacterium and Lactobacillus, both of 
which are saccharolytic, whereas some species such as Clostridium perfringes 
and Escherichia coli can be considered harmful (29, 86).  The human intestinal 
microbiota is affected by many factors such as age, drug therapy, disease, diet, 
host physiology, peristalsis, local immunity, and in situ bacterial metabolism (9).  
However, diet is probably the most significant factor determining the type of 
gastrointestinal microflora that develops since foodstuffs provide the main 
nutrient sources for colonic bacteria.   
GOS Human feeding trials 
Infants and pregnant mothers.  Born with an essentially sterile gastrointestinal 
tract, infants provide a unique opportunity to investigate the effects of prebiotics 
on the gastrointestinal microbiota.  Immediately after birth, the colonization of the 
infant gastrointestinal tract starts (73) and is influenced by the mode of delivery 
(8, 35), the composition of the maternal microbiota (87), and the mode of feeding 
– ie, breast milk or infant formula (37, 84).  Over a series of weeks and months, 
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infants become progressively colonized by different bacteria, which results in the 
establishment of an increasingly complex and stable microbiota.  Since the 
development of the gastrointestinal microbiota is profoundly influenced by the 
feeding regimen, those infants fed breast milk typically stimulate bifidobacteria to 
become dominant in the first few days of life (1, 53).  This dominance of 
bifidobacteria in the gastrointestinal microbiota of breast-fed infants (90-95% of 
total microbiota) can continue up through the first two years of an infant‟s life, and 
is fundamental for the well-being of the infant (13, 22, 92).  As discussed earlier, 
the explanation for this dominance of bifidobacteria in breast-fed infants is 
thought to occur due to the natural oligosaccharides, so called prebiotic factors, 
found in human milk.  Promoting this early gastrointestinal colonization with 
beneficial flora is thus important in infants, especially when breast milk is not 
available for various reasons.  Due to their complexity, oligosaccharides with 
structures identical to human milk are not yet available as dietary ingredients; 
however prebiotics similar to human milk oligosaccharides have proved 
promising.  The development of improved infant formulas that emulate the 
beneficial effects of human milk by supplementing specific prebiotics that 
selectively stimulate beneficial indigenous bacteria such as bifidobacteria, has 
gained considerable interest.   
 Infant and neonate studies are probably the area most extensively 
researched using GOS as a prebiotic supplement for infant formulas.  The 
majority of the trials, listed in Table 2, have focused on demonstrating the  
  
1
4
 
Table 2. Infant and pregnant mother studies with the prebiotic galactooligosaccharide (GOS) 
 
        Length                                                                                          
Type        Dose  Subjects  No of study  Objectives  Result           Reference 
 
Randomized      _  Neonates              4 trials 14-33 days Efficacy and safety of  No significant difference          Srinivasjois        
Control Trials     ≤ 37 weeks           (n=126)   GOS supplementation in weight, higher   et al. (2009) 
(RCT)          in reducing the incidence bifidobacteria colony 
          of sepsis and improving counts, lower pathogenic 
          physical growth  bacteria colony counts 
 
Double-blind                  scGOS/lcFOS Healthy term          n=215 first 26 weeks Explore the effect of  No significant differences Raes  
randomized                       (9:1) 6 g/d  infants     infant milk formula (IMF) seen in white blood count, et a(2009) 
controlled trial         during the first 26 weeks lymphocyte numbers, or   
(DBRCT)             immunoglobulins  
 
Double-blind               scGOS/lcFOS  Breast fed              n=63; 57  4 months  Determine if prebiotics or    Prebiotic fed infants tend to Bakker-Zierikzee             
randomized                      (9:1) 6 g/d,  and formula     probiotics should be used  have a higher percentage of  et al. (2005) 
                          6.0E10 Bifidobacterium fed infants    to reach a gut flora  bifidobacteria counts compared 
                         animalis viable cells      dominant by bifidobacteria to those of prebiotic fed infants 
 
DBRCT, scGOS/lcFOS  Formula fed           n=284 52 weeks  Evaluate infant formulas Incidence of diarrhea Chouraqui   
Parallel group          (9:1) 4 g/L plus term infants    containing probiotics and significantly lower in  et al. (2008) 
           3 different prebiotic      synbiotics for safety and  prebiotic group, stool  
           combinations        tolerance   frequency significantly  
higher with synbiotics 
 
DBRCT           5 g/L GOS, control Formula fed          n=159 12 weeks  Determine bifidogenic  At weeks 6 and 12 a Fanaro  
     term infants    effects of GOS in a follow- higher median number et al. (2008) 
  on formula  of bifidobacteria was observed 
     in the GOS vs. control group 
 
DBRCT          scGOS/lcFOS  Hypoallergenic     n=84 6 months  Analyze the effect of  Significant reduction in  van Hoffen  
          (9:1) 8 g/L, control formula fed    GOS/FOS on the immune plasma level of total  et al. (2009) 
term infants     response in infants         IgE, IgG1, IgG2, and  
        IgG3 
 
Randomized         0.24 g/100mL  Formula fed          n=164 3 months  Investigate the effect of Intestinal bifidobacteria, Ben  
controlled study    term infants    infant formula supplemented lactobacilli, acetic acid,  et al. (2008) 
          with low levels of GOS on and stool frequency were  
          intestinal micro-flora and  significantly increased.  
          fermentation characteristics stool pH decreased 
 
Double-blind         4 g/L GOS,  Formula fed         n=117 28 days  Investigate effects of No significant changes Nakamura 
controlled                         Other prebiotics term infants    prebiotic blends on fecal in bacterial populations et al. (2009) 
          bacterial populations for GOS or other blends 
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Table 2. Continued 
 
        Length                                                                                          
Type        Dose  Subjects  No of study  Objectives  Result           Reference 
 
DBRCT           scGOS/lcFOS  Preterm                 n=113 30 days  Determine the effect of No significant reduction Westerbeek 
          (8:2) increasing  infants     enteral supplementation of serious endogenous  et al. (2010) 
          dose (max=1.25 g/kg)      of prebiotic mixtures on  infection but trend toward 
          serious infectious morbidity  lower incidence 
 
Pregnant Mothers: 
 
DRBCT          GOS/lcFOS  Pregnant              n=48 week 25-delivery Determine how    GOS/lcFOS exhibits a  Shadid 
          (9:1) 3 g; 3 times women     supplementation with GOS bifidogenic effect on  et al. (2007)  
          a day (9 g/d)  vaginal delivery    and lcFOS in the last maternal gut microbiota  
          trimester of pregnancy affects  but does not transfer to 
          maternal and neonatal gut  neonates 
microbiota        
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abilities of GOS to increase fecal bifidobacteria populations.  However, a study 
done by the Nakamua group (2009) did not see any significant differences in 
change of bacterial populations, but stated the age related differences involved in 
this study indicated that the GOS blends may have a greater impact on younger 
infants.  With an increase in the fecal bifidobacteria populations, studies 
performed by Bakker-Zierikzee et al. (2005), Xiao-Ming et al. (2008), and 
Srinivasjois et al (2009) also exhibited a decrease in fecal pH with more frequent, 
softer stools.  Srinivasjois et al (2009) found that the decrease in fecal pH 
restricts the growth of potential pathogens, which mimics the pH of breast-fed 
infants.  In addition to the bifidogenic effects, it has been suggested that breast 
feeding reduces the incidence of allergic disorders in children, in particular atopic 
dermatitis and wheezing (25).  When the effect of GOS/FOS on the immune 
response in infants was analyzed by E. van Hoffen and colleagues (2009), a 
significant reduction in the total Ig response was observed.  In addition, the 
GOS/FOS ratio (9:1) modulated the immune response toward cow’s milk protein 
(CMP), leaving the response to vaccination intact.  Raes et al (2009) further 
explored the effects that GOS has on the basal immune parameters during the 
first 26 weeks of life and found that there was no change when compared to the 
developing immune system in healthy breast-fed infants.  Several of the studies 
also observed that GOS did not affect weight gain, crying, regurgitation, and 
vomiting (Table 2).  A study done by Shadid and colleagues (2007) also explored 
how supplementation with GOS in the last trimester of pregnancy affected 
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maternal and neonatal gastrointestinal microbiota.  They found that the 
supplementation had a bifidogenic effect on the maternal gastrointestinal 
microbiota that is not directly transferred to the neonates. Results suggested 
however, that maternal microbiota plays a role in the initial colonization of the 
infant gastrointestinal tract during the first days of life, as assessed by the high 
similarity index (SI; 60%).  The continued research on infants shows that the 
incorporation of manufactured prebiotics such as GOS can be a useful addition 
to formula feeds in order to replicate some of the functional attributes associated 
with breast milk, particularly its bifidogenic effects; especially with breast milk is 
not available.       
Healthy adults.  Since gastrointestinal health can be controlled artificially 
(introduction of prebiotics), the diet might be the most important regulating factor.  
As infants, the number of bifidobacteria is the dominant bacterial group, even for 
bottle-fed infants now that supplementation of prebiotics has been explored.  
After solid food introduction and weaning from formula or breast milk, the number 
of bifidobacteria decrease dramatically as bacteroides and firmicute groups 
become dominant with advanced aging.  Due to the beneficial effects that 
bifidobacteria exert on their host, as discussed earlier, efforts to increase 
bifidobacteria populations in adult humans are rapidly growing.  Introduction of 
functional foods, in particular prebiotics, has taken the attention of diet 
supplementation to a more advanced level beyond human milk oligosaccharides.  
Studies are no longer just focusing on effects in infants, but rather are turning 
18 
 
their attention to the bifidogenic effects seen in adults, and the possible 
correlation that exists between increased bifidobacteria and health.   
 Several studies involving healthy human adults have been performed to 
determine the effects that GOS has on the gastrointestinal microbiota (Table 3).  
Studies performed by Ito et al (1990; 1993), Alles et al (1999), Depeint et al 
(2008), Davis et al (2010), and Alander et al (2001) showed that GOS greatly 
increased bifidobacteria populations and in some cases exhibited a linear-like 
relationship between the amount of GOS and the number of bifidobacteria in the 
feces.  Effects of GOS on blood lipid concentrations, glucose absorption, and 
calcium and nonheme-iron absorption were also studied in humans.  W van 
Dokkum and colleagues (1999) showed that 15g of GOS was well tolerated with 
subjects however, beyond increased flatulence the GOS effects were limited.  
They observed not cholesterol lowering effects and there was no alteration in 
blood lipid concentration or glucose absorption.  Similar results were observed by 
van den Heuvel and colleagues (1998), as they did not observe any affect on iron 
or calcium absorption with the consumption of 15g/day of GOS.  An additional 
study by van den Heuvel et al (2000) explored the effects of GOS on calcium 
absorption in postmenopausal women and observed an increase in calcium 
absorption by 16% however, this was not accompanied by increased urinary 
calcium excretion.  This observation implies that GOS may indirectly increase 
calcium uptake by the bones and/or inhibit bone resorption in postmenopausal 
women.  Research done by Davis et al (2010) showed that a bifidogenic dose  
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Table 3. Healthy adult studies with the prebiotic galactooligosaccharide (GOS) 
 
        Length                                                                                          
Type        Dose  Subjects  No of study  Objectives  Result           Reference 
                   
 
Latin square          3 treatments of Healthy Men           n=12 12 weeks  Study effect of 15 g/d For GOS; significantly van Dokkum 
randomized          inulin, FOS, and      nondigestible   higher fecal wet weight, et al. (1999) 
double-blind          GOS (15 g/d)       oligosaccharides   acetic acid. Significantly  
diet controlled            lower fecal dry weight. 
              Increase in flatulence 
  
Double-blind          20 g/d TOS  Postmenopausal    n=12 37 days  Investigate whether  Increased Ca absorption van den Heuvel  
randomized    women     TOS stimulates true  observed due soley to TOS et al. (2000) 
cross-over study         Ca absorption  in  
          postmenopausal  
          women with decreased 
          efficiency of Ca absorption 
 
Randomized          3 treatments of Nonanemic             n=12 12 weeks  Effects of nondigestible No significant differences van den Heuvel 
cross-over study          inulin, FOS, and men     oligosaccharides on  were observed with respect et al. (1998) 
           GOS (15 g/d)       metabolism/absorption of to iron or Ca absorption in any 
          calcium or iron in humans of the treatments 
 
Single-blind          52% GOS  Healthy adults        n=12 7 weeks  Effects of GOS on microflora, Linear relationship between Ito et al (1990)  
cross-over study          0, 2.5, 5, or 10 g/d      stool weight, abdominal  amount of GOS and increase 
          tolerance, and laxative in bifidobacteria. Lactobacilli 
          similarities  slightly increased with dose 
 
Single-blind         93% GOS  Healthy adults        n=18 16 weeks  Determine the effect of Significant increase of  Davis 
randomized         0, 2.5, 5, or 10 g/d      different doses of GOS on bifidobacteria was seen et al. (2010) 
          the fecal microbiota of  after 5.0 g/d in 50% of the 
          healthy adults with a focus subjects.  
          on bifidobacteria  
 
Double-blind        15 g/d GOS  Japanese               n=12 6 days  Effects of GOS after  Bifidobacteria and   Ito et al. (1993) 
randomized    men     ingestion on the human Lactobacilli significantly 
cross-over  study         microflora and metabolism increased.  Bacteroides 
             and Canidida significantly 
             decreased. Bifidobacteria 
             percentage of total bacteria 
             increased. 
 
Parallel         7.5 g/d or 15 g/d Healthy adults        n=18 (W) 3 weeks  Compare the effect of Increase in bifidobacteria  Alles et al. (1999) 
single-blind                   n=22 (M)   two doses of GOS on the was seen but not significant. 
          gut microbiota composition No other significant changes 
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Table 3. Continued 
 
        Length                                                                                          
Type        Dose  Subjects  No of study  Objectives  Result           Reference 
                   
 
Randomized         GOS/probiotic mix Healthy adults         n=38 8 weeks  Investigate the effects of  There was not significant Tiihonen 
parallel-design         3.8 g/d GOS to mix Male wistar rats       n=40   prebiotic supplementation effect with the rats on  et al. (2008) 
                on a probiotic bacteria mix bacteria population.  Increase  
             in bifidobacteria numbers 
             observed in humans but not 
             significant  
 
Double-blind         2.5 g/d of GOS  Healthy adults         n=15 15 weeks  Determine the effect of  Increased metabolic activity Tannock  
cross-over study         or FOS       GOS containing biscuits but not necessarily   et al. (2004) 
          on the composition and  increased bifidobacteria 
          activity of the fecal  numbers. Increased staining 
          microflora   in Bifidobacterium adolescentis 
 
Randomized        8.1 g/d GOS  Healthy adults         n=30 6 weeks  Further develop the PCR- Changes detected were not Malinen 
Single blinded study       with B. lactis Bb-12      ELISA methods to follow consistent  et al. (2002) 
          fluctuations in bifidobacteria 
 
Randomized        8.1 g/d GOS  Healthy adults         n=30 6 weeks  Investigate the effect of 5 adults showed changes Satokari   
Single blinded study       with B. lactis Bb-12      GOS and/or the probiotic  in the DGGE profile of et al. (2001) 
          strain on composition of  bifidobacteria.  The prebiotic 
          indigenous bifidobacteria  did not prolong the persistence 
          populations using PCR- of the probiotic strain 
          DGGE 
 
 
Randomized        8.1 g/d GOS  Healthy adults         n=30 6 weeks  Effect of GOS-containing  Mean numbers of   Alander   
Single blinded study       with B. lactis Bb-12      syrup on colonization and bifidobacteria increased et al. (2001) 
          persistence of B. lactis slightly in all subjects. 
          Bb-12 in the gastrointestinal Probiotic strain was not 
          tract    enhanced for survival or 
             persistence by GOS 
 
Double-blind        0.0, 3.6, and 7.0 g/d Healthy adults        n=59 4 weeks  Access prebiotic potential Probiotic GOS   Depeint 
randomized        GOS from B. bifidum      of GOS produced through significantly increased et al. (2008) 
cross-over study        7.0 g/d industrial GOS      β-galactosidases from the  bifidobacteria numbers  
          probiotic B.bifidum against  after 7.0 g/d.  Significant  
          industrial GOS  relation to bifidobacteria  
             proportion and probiotic  
             GOS dose observed   
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Table 3. Continued 
 
        Length                                                                                          
Type        Dose  Subjects  No of study  Objectives  Result           Reference 
                   
 
DBRCT                        10 g/d of GOS powder Healthy adults        n=8 21 days  Assess tolerance of  Bifidobacteria concentration Bouhnik 
          GOS and the effect that was significantly higher  et al. (1997) 
          10 g/d administration has  after day 7, 14, 21  
          on fecal concentrations of  compared to day 1. Breath 
          bacteria    H2 was significantly lower 
             on day 7, 14, 21 compared 
             to day 1 
 
DBRCT                       7 non-digestible  Healthy adults        n=200 5 weeks  Determine the bifidogenic GOS was found to be  Bouhnik 
Parallel study       carbohydrates  (NDCH)      potential of different NDCH bifidogenic.  A linear  et al. (2004) 
        Including GOS       used in human diets and dose relationship      
        2.5, 5.0, 7.5, or 10 g/d      determine a dose response was found  
 
DBRCT        15 g/d GOS  Healthy adults         n=12 2 weeks  Determine fecal frequency Defecation frequency  Teuri et al. (1998) 
          and gastrointestinal  and flatulence increased 
          symptoms associated with  Fecal bifidobacteria did not 
          ingestion of GOS containing show an increase 
          yogurt  
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dependent response occurred in half of the subjects, indicating a possible 
‘responders’ effect in healthy adults.  This ‘responders’ and ‘non-responders’ 
theory can be explained by the presence or absence of specific bifidobacteria 
strains capable of using GOS as a growth substrate, however what actually 
differentiates these two groups  is still unknown.  In several of the studies, a 
prebiotic effect was not observed at GOS dosage levels below 5.0 g (Table 3), 
which indicates that a level of at least 5.0 g is needed to elicit a bifidogenic effect.  
All of the studies reported a return to the initial bifidobacteria population once the 
consumption of GOS was no longer continued, indicating the stability of the 
gastrointestinal microbiota of adults.  This return to the initial levels of microbiota 
also indicates that continual consumption of GOS, or the selected prebiotic, will 
be needed in order to maintain the increased levels of bifidobacteria required for 
health benefits and disease prevention.  The GOS, even at levels of 15 g/day, 
was well tolerated by adults throughout all of the studies, with only a slight 
increase in flatulence detected.  These studies also showed that GOS can be 
incorporated into powders, liquids, or solid foods and still exhibit the same 
prebiotic effects, which is beneficial to the food industry as products are 
continually being developed.  The future of prebiotics, especially GOS, is 
promising for the health of human adults, however further research is needed to 
fully understand all of the effects and the possible relationships to diseases.       
Elderly adults.  As life expectancy throughout the world has rapidly risen, 
heightened attention has been placed on physiologic and health needs of those 
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persons over the age of 60 years.  Aging is associated with changes in the 
function of many organs and tissues, including the gastrointestinal tract.  The 
gastrointestinal microbiota evolves with age and the composition of the elderly 
microflora differs from that of younger adults and infants (100).  Putrefactive 
bacteria, such as clostridia and enterobacteria have been reported to increase in 
several studies, at the expense of more beneficial groups, most importantly 
bifidobacteria (27, 40, 58, 59).  The aging process is also associated with a 
marked decline in immune function (immunosenescence), which can promote 
hyporesponsiveness to vaccination and a predisposition to infectious and 
noninfectious diseases (5).  The intake of food and fluid also decreases, as does 
physical activity in elderly adults.  This, in combination with the use of a wide 
range of medication that elderly people often use, can cause constipation.  As 
described earlier, reports of increased indigenous bifidobacteria in infants and 
adults have been observed with the supplementation of GOS in the diet.  
Studies, however, have not fully determined their effect on elderly persons.  
Recent research has turned its focus to the use of prebiotics, in particular GOS, 
in order to increase bifidobacteria populations in elderly with hopes of increased 
immune function as well as relief of constipation.   
 For elderly human subjects, data is scarce and contradictory for 
modulation of the gastrointestinal microflora by GOS, however results are 
promising (Table 4).  Studies performed by Ito et al (1993) and Vulevic et al 
(2008) showed that administration of GOS, at as little as 2.5 g/day, resulted in a  
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Table 4. Elderly adult studies with the prebiotic galactooligosaccharide (GOS) 
 
        Length                                                                                          
Type        Dose  Subjects  No of study  Objectives  Result           Reference 
                   
 
Single-blind          2.5 g/d of GOS Elderly Men            n=12 3 weeks  Determine the effect of  Number of bifidobacteria Ito et al. (1993) 
randomized         GOS on the human fecal was slightly increased  
controlled study         microflora on elderly  after consumption of  
          persons who have low  GOS 
          indigenous bifidobacteria 
 
Double-blind         10 g/d of GOS  Elderly adults         n=41 56 days  Evaluate the diversity and  No effect to diversity and Maukonen  
placebo controlled    self-reported    temporal stability of   temporal stability of selected et al. (2008) 
randomized     constipation    predominant fecal bacteria bacterial groups was observed. 
cross-over study         populations in elderly  Elderly did exhibit higher  
          suffering from constipation numbers of predominant  
             groups than younger adults 
 
Double-blind         5.5 g/d of GOS  Elderly adults         n=44 28 weeks  Assess the effect of a  GOS significantly increased Vulevic  
placebo controlled         prebiotic GOS mixture bifidobacteria, phagocytosis, et al. (2008) 
randomized         on immune function and  NK cell activity, and anti- 
cross-over study         fecal microflora of elderly inflammatory cytokine 
          adults   interleukin-10.  A significant 
             reduction in pro-inflammatory 
             cytokines was also observed 
 
Double-blind         9 g/d of GOS  Elderly adults         n=14 6 weeks  Investigate whether a Weekly defecation frequency Teuri et al. (1998) 
two period    Females     daily intake of 9 g/d of  was higher and stools were 
cross-over study         GOS relieves constipation softer during GOS consumption 
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significant increase in bifidobacteria.  Vulevic and colleagues (2008) also 
observed that at 5.5 g/day, there was a significant decrease in less beneficial 
bacterial, which suggests that GOS is an attractive option for enhancement of 
both the gastrointestinal tract and immune system.  Another study performed by 
Maukonen and colleagues (2008), showed contradictory results as consumption 
of GOS did not significantly affect the diversity or temporal stability of selected 
bacterial populations.  Reasons for this could be associated with the type and 
purity of the GOS used, or linked to the ability of the selected subjects to respond 
to the GOS, as discussed earlier.  A study by Teuri and colleagues (1998) 
focused on relieving constipation in elderly through consumption of GOS.  They 
observed a higher frequency of defecation along with softer stool sample.  A 
dose of 9 g/day of GOS relieved constipation by making defecation easier.  Due 
to the fact that laxatives often have unwanted side effects and some humans are 
able to build up a gastrointestinal tolerance, an alternative for the use of laxatives 
in elderly to relieve constipation has gained considerable attention.  GOS has 
proven to be a promising alternative as some researchers have suggested that a 
reduction in the number of bifidobacteria has been related to constipation and 
thus treatment with GOS increases the number of bifidobacteria can therefore 
benefit bowel function (36), however further research is still needed.            
Gastrointestinal diseases.  Irritable bowel syndrome (IBS) is the most common 
functional gastrointestinal disorder.  Multidisciplinary approaches have been 
proposed based on what is known of its pathophysiology, however IBS continues 
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to represent a significant therapeutic challenge (50, 81).  Current interest has 
focused on the role of the gastrointestinal microbiota-mucosa interactions linked 
to inflammatory and immune processes.  With studies finding benefits pointing to 
the increase in the bifidobacteria populations by the use of the prebiotic GOS, 
studies are now investigating the efficacy of GOS as therapy in patients with IBS.   
 The use of GOS as therapy for IBS patients is very recent and not well 
explored.  In an animal study performed by Holma et al (2002), an increase in 
bifidobacterial numbers was observed however, there was no reduction in 
inflammatory processes with the consumption of GOS.  A clinical trial by Silk et al 
(2009) found that GOS had bifidobacterial enhancing effects in IBS patients at a 
dose of 3.5 g/day and 7.0 g/day (Table 5).  This increase in the levels of 
bifidobacteria became similar to those of healthy humans.  They also reported 
that consumption of GOS was effective in alleviating symptoms associated with 
IBS.  These findings, although several more studies are needed, suggest that the 
prebiotic GOS has the potential to act as a therapeutic agent in IBS, which is a 
significant step forward.  
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Table 5. IBS adult studies with the prebiotic galactooligosaccharide (GOS) 
 
        Length                                                                                          
Type        Dose  Subjects  No of study  Objectives  Result           Reference 
                   
 
Randomized         3.5 or 7.0 g/d of GOS Rome II                n=44 12 weeks  Investigate the efficacy GOS treatment resulted in Silk et al. (2009 
parallel     positive IBS    of a novel prebiotic in  significantly higher  
cross-over study         changing the colonic proportions of bifidobacteria. 
          microflora and improve 7.0 g/d resulted in significantly 
          IBS symptoms     lower C. perfringens and bacteroides 
             populations.  Reported improved 
             stool consistency, flatulence, bloating, 
             and composite score symptoms       
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Conclusion 
Prebiotics, especially GOS, are commonly being used as functional ingredients in 
infant formulas as well as a variety of food products.  The consumption of GOS 
has unquestionably been shown to have a wide variety of metabolic 
consequences in the human gastrointestinal tract.  A vast majority of the 
investigations into GOS and its effects on the human gastrointestinal microflora 
have shown its selectivity toward only a few bacterial groups, mainly 
bifidobacteria.  This selectivity has usually only been characterized to the genus 
level, however researchers are beginning to take advantage of the advanced 
analytical technologies that have become available for detailed community 
analysis.  Utilizing these advanced technologies, the global effect of prebiotic use 
on microbial community structure will begin to shed light on the possibilities that 
prebiotic consumption has.  Characterizing these populations beyond the genus 
level will also help in providing which species have distinct health-promoting 
properties, as it is unlikely that all of the bifidobacteria colonizing the colon do.  
Future work with well designed human investigations is still needed to establish 
prebiotic needs.  In particular, further studies are needed to establish the 
potential role of dietary manipulation for allergy/disease prevention, immune 
modulating effects of prebiotics in babies and in elderly, and to ascertain whether 
these effects are long lasting.  The optimal dose of GOS for specific subject 
groups also needs to be determined to help in selecting the proper treatment 
prior to consumption.  In addition, processing procedures may alter the prebiotic 
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carbohydrate profile in food, which could subsequently affect the digestion and 
fermentation pathways.  Therefore, an understanding of whether the prebiotic 
activity is maintained after food processing treatments is needed to substantiate 
the use of GOS as a functional food ingredient.  GOS as a prebiotic has 
undoubtedly played a role in the treatment of IBD however, it is important that 
systematic studies are instigated to test for GOS benefits on all levels, as well as 
within a variety of age groups.  The future holds promise as a considerable 
amount of prebiotic literature and research is quickly taking off.     
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Abstract 
The goal of this research was to determine the effect of different doses of 
galactooligosaccharide (GOS) on the fecal microbiota of healthy adults, with a 
focus on bifidobacteria.  The study was designed as a single-blinded study, with 
eighteen subjects consuming GOS-containing chocolate chews at four increasing 
dosage levels; 0, 2.5, 5.0, and 10.0 g.  Subjects consumed each dose for 3 
weeks, with a two-week baseline period preceding the study and a two-week 
washout period at the end.  Fecal samples were collected weekly and analyzed 
by cultural and molecular methods.  Cultural methods were used for 
bifidobacteria, Bacteroides, enterobacteria, enterococci, lactobacilli, and total 
anaerobes; culture-independent methods included denaturing gradient gel 
electrophoresis (DGGE) and quantitative real-time PCR (qRT-PCR) using 
Bifidobacterium-specific primers.  All three methods revealed an increase in 
bifidobacteria populations, as the GOS dosage increased to 5 or 10 g.  
Enumeration of bifidobacteria by qRT-PCR showed a high inter-subject variation 
in bifidogenic effect and indicated a subset of 9 GOS responders among the 
eighteen subjects.  There were no differences, however, in the initial levels of 
bifidobacteria between the responding individuals and the non-responding 
individuals.  Collectively, this study showed that a high purity GOS, administered 
in a confection product at doses of 5 g or higher, was bifidogenic, while a dose of 
2.5 gram showed no significant effect.  However, the results also showed that 
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even when GOS was administered for many weeks and at high doses, there 
were still some individuals for which a bifidogenic response did not occur. 
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Introduction 
The large intestine of humans harbors a complex, cell rich, and diverse microbial 
community consisting of hundreds of different bacterial species (Eckburg et al., 
2005; Moore et al., 1978).  Included within this microbiota are organisms whose 
presence is associated with, or that contribute to the health of the host (Neish, 
2009).  In particular, bifidobacteria have long been suggested to play an 
important prophylactic and therapeutic role in colonic health (Leahy et al., 2005).  
Although these bacteria are present in large numbers in infants, and are the 
dominant group in breast-fed individuals, they become less numerous after 
weaning (Fooks and Gibson, 2002; Mackie et al., 1999).  Due to the suggested 
health benefits these bacteria provide to the host, efforts to enrich the 
bifidobacteria population are now of considerable interest. 
One of the primary ways by which the composition of the intestinal microbiota 
can be modified is via introduction of prebiotics into the diet (Gibson and 
Roberfroid, 1995; Roberfroid, 1998).  Currently, a prebiotic is defined as “a 
selectively fermented ingredient that allows specific changes, both in the 
composition and/or activity in the gastrointestinal microbiota that confers benefits 
upon host well-being and health” (Roberfroid, 1998).  Among the most widely 
studied and commercially used prebiotics are inulin, fructooligosaccharides 
(FOS), and galactooligosaccharides (GOS).  The latter refer to a group of 
oligomeric, non-digestible carbohydrates that are produced from lactose using β-
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galactosidases to catalyze transgalactosylation reactions (Macfarlane et al., 
2008; Sako et al., 1999).  These β-linked glycosides are recalcitrant to digestion 
by host-secreted enzymes in the small intestine, such that they reach the colon 
intact.  They then become available to those members of the colonic microbiota 
metabolically equipped to metabolize these specific oligosaccharides (Alander et 
al., 2001; Ito et al., 1993; Tannock et al., 2004). 
Numerous in vivo studies have assessed the effect of GOS on the intestinal 
microbiota of infants (Chouraqui et al., 2008; Fanaro et al., 2008; Nakamura et 
al., 2009), pre-term infants (Westerbeek et al., 2010), pregnant women and 
neonates (Shadid et al., 2007), intestinal bowel disease patients (Silk et al., 
2009), elderly adults (Maukonen et al., 2008, Sairanen et al., 2007; Teuri and 
Korpela, 1998), and healthy adults (Alander et al., 2001; Alles et al., 1999; 
Bouhnik et al., 1997, 2004; Malinen et al., 2002; Satokari et al., 2001; Tannock et 
al., 2004; Tiihonen et al., 2008; Vulevic et al., 2008 ).  These studies used doses 
ranging from as little as 2.5 g per day of GOS to as high as 15 g per day, and 
relied on cultural as well as molecular methods to measure changes in the 
microbiota.  Although significant increases in the bifidobacteria population were 
observed in several of these studies (Bouhnik et al., 1997, 2004; Depeint et al., 
2008; Vulevic et al., 2008), in other studies bifidogenic effects were not apparent 
(Alles et al., 1999).  Differences in the type, purity, and composition of the GOS 
used in these studies, as well as difference in experimental design and methods 
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of analysis, have likely contributed to these varying outcomes (Macfarlane et al., 
2008). 
The goal of this study was to obtain a more detailed understanding of the effect 
of GOS on the composition of the human gut microbiota and to determine the 
dose necessary to achieve a prebiotic or bifidogenic effect. Both culture-based 
and molecular methods were used to enumerate and characterize shift in 
selected bacterial populations in eighteen blinded subjects that consumed GOS 
that had been incorporated into a caramel-like, chewable confection product.  
The experiment was designed such that subjects were given these GOS-
containing products in sequentially higher doses (from 2.5 g to 10 g per day) so 
that the dosage necessary to elicit a bifidogenic effect could be determined. 
 
Materials and methods 
Preparation of chocolate chews 
Chocolate-flavored chewable candies (chews) containing GOS and control 
chews (with no GOS) were prepared at the University of Nebraska-Lincoln Food 
Processing Center.  The GOS used was Purimune™, a high purity GOS powder 
(91.8% on a dry basis) provided by GTC Nutrition (Golden, CO).  The balance of 
the GOS contained lactose (7%), glucose (<1%), and galactose (<0.5%).  The 
chocolate chews were formulated to contain 1.25 g of GOS per 6 g chew.  
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Additional corn syrup and sucrose were included in the control chews containing 
no GOS.  The formulations of both the GOS and control chew are shown in Table 
1.  Chews were wrapped individually in wax paper and stored in sealed plastic 
bags at 20˚C.  The chews were distributed to subjects on a weekly basis. 
Experimental design 
The study included 21 healthy human volunteer subjects that were recruited on 
the University of Nebraska-Lincoln campus.  None of the subjects had been on 
antibiotics or on a vegetarian diet within three months prior to the start of the 
study or during the study.  Subjects were allowed to maintain their normal 
lifestyles without any additional restrictions on their diets.  Two subjects dropped 
out of the study for reasons unrelated to the experiment and one subject was 
released from the study due to pregnancy.  Thus, a total of eighteen subjects, 13 
males and 5 females, between the ages of 19 and 50 years old, completed the 
study.  The study was conducted over a 16 week period.  A two-week baseline 
period (no chews administered) was conducted at the beginning of the study, 
followed by four sequential testing periods during which chews were 
administered for three weeks with GOS dosages at levels of 0.0 g, 2.5 g, 5.0 g, 
and 10.0 g GOS per day.  Subjects were blinded in terms of the dose of GOS 
they received, and instructed to consume eight chews per day during each 
testing period, with the only difference being the number of GOS-containing 
chews included in the daily regimen, which could not be differentiated from 
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control chews.  Thus, during the control period, 8 control chews were consumed, 
and during the 2.5 g treatment period, 2 GOS chews (each containing 1.25 g 
GOS) and 6 control chews were consumed.  The 5 g treatment period included 4 
GOS and 4 control chews and the 10 g treatment consisted of 8 GOS chews.  A 
final two-week washout period (no chews) was performed at the end of the fourth 
testing period.  All of the dosages were sequential with no washout periods 
between dosages.  Subjects were asked to report the presence, absence, and 
severity of gastrointestinal symptoms experienced throughout each week of the 
study.  The symptoms survey was based on previously reported studies (Bouhnik 
et al., 1997, 2004; Shadid et al., 2007) and included bowel movement, stool 
consistency, discomfort, flatulence, abdominal pain, and bloating, and were 
scored on a one (none, normal, good well-being) to five (severe symptoms and 
discomfort) scale provided as part of weekly subject diaries.  The study was 
approved by the Institutional Review Board of the University of Nebraska. 
Collection and processing of fecal samples 
Fecal samples were collected weekly from each subject.  Each sample was 
processed within 1 hour of a bowel movement.  All fecal samples (1.0 g) were 
weighed and diluted 10-fold with sterile phosphate buffered saline (PBS; pH 7.0).  
Samples were homogenized and immediately frozen at -80°C and saved for DNA 
extraction.  Fecal samples (1.0 g) were also immediately introduced into an 
anaerobic chamber (Bactron IV Anaerobic Chamber, Shel Lab, Cornelius, OR) 
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and a 10-fold dilution series was made with pre-reduced sterile saline (0.9% 
NaCl).  Aliquots were plated on Brain Heart Infusion Agar (Becton Dickinson; BD, 
Franklin Lakes, NJ) for total anaerobes (incubated 48 h), Rogosa SL (BD) for 
Bifidobacterium (96 h), and Bacteroides Bile Esculine Agar (BD) for Bacteroides 
(48 h).  All plates were incubated anaerobically at 37°C.  In addition, the Rogosa 
SL agar plates that were used to enumerate bifidobacteria were also examined at 
48 h to estimate lactobacilli levels.  Serial dilutions were also used to plate 
aliquots aerobically on MacConkey Agar (BD) for enterobacteria (24 h), and Bile 
Esculin Azide Agar (Acumedia, USA) for enterococci (48 h).  Plates were 
incubated aerobically at 37°C.  These organisms were chosen for cultural 
enumeration based on previous prebiotic and probiotic feeding studies (Tannock 
et al., 2000, 2004). 
The fecal pH was measured in aqueous slurries using an Ag/AgCl pH meter 
(Accumet Basic AB15pH meter, Fisher Scientific).  Statistical analysis was 
completed using a one-way ANOVA as well as Tukey’s post-hoc pair-wise 
comparison test.   
DNA extraction 
A 1 mL aliquot of a 1:10 diluted fecal sample in PBS was transferred to sterile 
bead beating tubes (Biospec products, Bartlesville, OK, USA) containing 300 mg 
of zirconium beads (0.1 mm).  Fecal cells were washed three times in chilled 
PBS using centrifugation at 6,000 x g for 5 min.  Pellets were resuspended in 100 
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µL of lysis buffer (200 mM NaCl, 100 mM Tris, 20 mM EDTA, 20 mg/mL 
Lysozyme, pH 8.0) and incubated at 37°C for 30 min.  Buffer ASL (1.6 mL) from 
the QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) was added to each 
sample after the samples were homogenized in a MiniBeadbeater-8 (BioSpec 
Products, OK, USA) for two min at maximum speed.  The DNA was purified from 
the supernatants using the QIAamp DNA Stool Mini Kit, following the Qiagen kit 
manufacturer’s instructions. 
Quantitative real time-PCR  
Quantitative real time PCR (qRT-PCR) was performed as described by Martínez 
et al. (2009) using a Mastercycler Realplex2 (Eppendorf AG, Hamburg, 
Germany) with Bifidobacterium-specific primers F: 
5’TCGCGTC(C/T)GGTGTGAAAG’3 and R: 5’CCACATCCAGC(A/G)TCCAC’3 
(Martínez et al. 2009, Rinttila et al. 2004), with an amplicon size of 243 bp.  
Standard curves for absolute quantification of bifidobacteria in the fecal samples 
were prepared using overnight cultures (14 h) of Bifidobacterium animalis ATCC 
25527T and Bifidobacterium infantis ATCC 15697T.  For each qRT-PCR 
experiment, a standard curve was prepared, in duplicate, using DNA extracted 
from cultures at concentrations ranging from 105-108 CFU/mL.  Correlation 
coefficients for all standard curves were above 0.95. 
Analysis by PCR-DGGE 
59 
 
PCR-DGGE was performed as described by Martínez et al. (2009). Briefly, the 
V3 region of the 16S rRNA gene was amplified by PCR using universal primers 
PRBA338fGC 
(5’CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGGACTCCT
ACGGGAGGCAGCAG’3) and PRUN518r (5’ATTACCGCGGCTGCTGG’3) 
(Ovreas et al., 1997).  Denaturing Gradient Gel Electophoresis (DGGE) was 
performed as described previously (Walter et al., 2000), using a DCode universal 
mutation detection system (Bio-Rad, Hercules, USA).  Band fragments of interest 
were excised, repeatedly purified (Walter et al. 2001), and then cloned using the 
TOPO® TA Cloning® Kit for Sequencing (pCR® 4 TOPO® Vector) (Invitrogen).  
The QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) was used to isolate 
plasmids from transformants, and inserts were sequenced by a commercial 
provider.  Closest relatives of the partial 16S rRNA sequences were determined 
using the SeqMatch web tool provided through the Ribosomal Database Project 
(http://rdp.cme.msu.edu). 
BioNumerics software Version 5.0 (Applied Maths) was used to analyze DGGE 
profiles.  DGGE bands were automatically assigned and densitometric curves 
were obtained based on the staining intensity profiles generated by the 
BioNumerics software.  Band staining intensities were calculated as a percent of 
each peak area of the entire fingerprint generated for the individual sample. We 
have previously determined the reliability of this quantification method by 
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comparing taxa abundance inferred by DGGE band intensities with those 
obtained with pyrosequencing of 16S rRNA tags in studies on the hamster 
microbiota, and received correlations of r > 0.8 (Martínez et al., 2009).     
Statistical analysis 
One-way ANOVA tests with repeated measures were used to determine 
significance between the different doses of GOS (0, 2.5 g, 5 g, and 10 g) and the 
control.  Baseline/washout samples were combined for the analysis and referred 
to as “none”’.  Statistical analysis was performed for the combined data from the 
eighteen subjects and to identify statistically significant increases of individual 
subjects. Tukey’s test was used for post hoc pair-wise comparisons. 
 
Results 
Digestive tolerance of GOS  
All eighteen subjects completed a weekly symptoms diary throughout the 
duration of the study.  These symptoms diaries allowed subjects to rate bowel 
movement, stool consistency, discomfort, flatulence, abdominal pain, and 
bloating on a scale of one (none, normal, good well-being) to five (severe 
symptoms and discomfort).  Based on a one-way ANOVA of the data, no 
significant differences were detected for any of the symptoms between the 0.0 g 
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GOS control dose and any of the GOS treatments (Table 2).  A significant 
symptom change was observed for flatulence (p < 0.05), but only between the 
baseline and washout and the treatment periods.  However, the increase in this 
score occurred not only for the GOS treatments, but even during consumption of 
the 0.0 g GOS control period. 
Fecal bacteria counts 
Cultural enumerations were performed for total anaerobic bacteria and for 
lactose-fermenting enterobacteria, enterococci, Bifidobacterium, and 
Bacteroides.  Lactobacilli counts were very low (< 106/g) throughout the entire 
duration of the study, even during treatment periods (data not shown).  When the 
data for each individual subject was analyzed, the results revealed that for some 
subjects, statistically significant differences in several of these groups were 
observed following consumption of GOS (data not shown).  When the results of 
all eighteen subjects were pooled together, no significant changes were detected 
for levels of Bacteroides, enterococci, or lactose fermenting enterobacteria.  
However, ANOVA revealed that GOS induced a modest, but statistically 
significant increase of bifidobacteria compared to the control treatment (Table 3).  
This bifidogenic effect occurred when subjects had consumed the 5 g dose of 
GOS, and a further increase in dose to 10 g of GOS was not significant when 
compared to the 5 g dose.  In contrast, however, the 10 g dose did result in a 
significant increase in total anaerobes compared to the 2.5 g dose.  In addition, 
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we observed that the bacterial populations for all groups were similar during the 
baseline and washout periods. 
The pHs of all of the fecal samples (288) were determined.  All but two of the 
samples had pH values between 6.0 and 8.0, and there were no significant 
treatment differences in pH observed over the period of the study (data not 
shown).  
Genus specific qRT-PCR for enumeration of bifidobacteria 
The culture analysis indicated that a bifidogenic effect occurred due to 
consumption of GOS, and that this effect was detectable at doses of 5 g and 10 
g, with no significant differences between the two high doses.  In order to confirm 
these findings without a potential cultivation bias, cell numbers of bifidobacteria in 
fecal samples were quantified by genus-specific qRT-PCR.  As shown in Figure 
1a, the Bifidobacterium population in the eighteen subjects increased with the 
inclusion of chews containing different amounts of GOS.  As before for cultural 
enumeration, this increase reached statistical significance when 5 g and 10 g of 
GOS were consumed (p < 0.001).  The analysis also showed major differences in 
the dose response relationships in individual subjects. In total, Bifidobacterium 
numbers were significantly increased by GOS consumption in nine of the 
eighteen subjects as analyzed by ANOVA.  Figure 1b shows the numbers of 
bifidobacteria in these nine “responders”. This data showed an equivalent 
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gradual increase of bifidobacteria with dose, with no significant differences 
between 5 and 10 g of GOS.   
To determine if the baseline Bifidobacterium population influenced the prebiotic 
effect, we compared the initial bifidobacteria levels between responders and non-
responders.  The Student’s t test did not reveal any significant differences 
between these groups (data not shown), indicating that initial number of 
bifidobacteria did not determine whether any specific individual was a responder 
or non-responder. In contrast, the baseline cell count of bifidobacteria in subjects 
was a major determinant for the bifidogenic effect when this effect was based on 
the difference in actual numbers from the baseline to the average of the 5 and 10 
g treatments.  As shown in Figure 2A, initial levels of bifidobacteria directly 
correlated with the increase of bifidobacteria numbers.  However, the bifidogenic 
effect, expressed as the “log increase”, was inversely correlated with the initial 
bifidobacteria levels (Figure 2B).  In other words, subjects with low numbers of 
bifidobacteria had a higher potential for the prebiotic to induce a 100-1000 fold 
increase, while subjects that already possessed high levels of bifidobacteria were 
able to achieve an even higher increase in absolute numbers. 
Characterization of total fecal bacterial populations by PCR-DGGE 
To obtain a broader assessment of the impact of GOS on the fecal microbiota, 
we used a universal PCR-DGGE approach to determine the dynamics of the 
community fingerprints. These analyses revealed a high level of stability among 
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the gut microbiota in all of the subjects.  The DGGE gels corresponding to the 
eight subjects with the most pronounced changes in staining intensities upon 
consumption of GOS are shown in Figure 3.  Quantification of DGGE band 
intensities was then performed using BioNumerics software, as previously 
reported (Martínez et al., 2009), revealing several major effects (Table 4). 
The most consistent alteration in band staining intensity resulting from 
consumption of GOS was a band at the bottom of the DGGE gels (labeled as C, 
G, H, I, and L), that was present in five subjects, 2, 4, 14, 15, and 17 (Figures 3A 
and 3B).  Excision of the band and subsequent purification and DNA sequencing 
revealed that the band corresponded to Bifidobacterium adolescentis (Table 5).  
The staining intensity of this band clearly showed a dose dependent increase 
(Table 4), although differences were observed between subjects with respect to 
the effective dose (ranging from 2.5 – 10 g).  However, when the band intensity 
values from these five subjects were averaged, the results revealed that a 
bifidogenic effect occurred only when the GOS dose reached 10 g (Figure 3C). 
Collectively, the abundance of B.adolescentis, as determined by staining 
intensity, was remarkably quantitative and highly correlated to cell numbers as 
determined by qRT-PCR (Figure 3D).  Also, as shown in Figure 3 and Table 4, 
the increase in B. adolescentis was reversible and returned to the baseline level 
within a week of wash out.  Consumption of GOS also resulted in several other 
reversible alterations in the fecal microbiota; however, most of these alterations 
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related to a decrease in staining intensity of bands that corresponded to different 
colonic microorganisms (Table 5).  
 
Discussion 
The ability of GOS to effect changes in the microbiota of the human intestinal 
tract was first reported in 1993 (Ito et al., 1993).  Although increases in the 
bifidobacteria population in test subjects were reported in this and many other 
studies (Bouhnik et al., 1997, 2004; Depeint et al., 2008; Vulevic et al., 2008), in 
other investigations a bifidogenic effect of GOS was not detected (Alles et al., 
1999; Malinen et al., 2002). Variations in the GOS type, dosage, the delivery 
vehicle, and in the experimental design likely account for some of these different 
outcomes.  However, the methods of analysis may have also contributed to these 
differences, especially when enumeration was based primarily on cultural 
methods. 
In this study, three independent techniques (group-specific culturing, qRT-PCR, 
and PCR-DGGE) were used to study the impact of different doses of a highly 
pure source of GOS on the human gut microbiota in eighteen healthy subjects.  
The GOS was incorporated into chewable confections, delivered in sequentially 
higher doses, and all of the subjects were blinded.  Samples were obtained and 
analyzed three times during each of the four treatment periods, and twice during 
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both the baseline and washout periods.   In general, the cultural enumeration 
results during the baseline period were consistent with other reports utilizing 
similar techniques to quantify members of the gastrointestinal microbiota 
(Tannock et al., 2000, 2004).  The low levels of lactobacilli in most of the subjects 
throughout the study were also consistent with previous observations (Eckburg et 
al., 2005; Tannock et al., 2000; Walter, 2008).  Importantly, however, all three 
methods clearly confirmed a highly significant bifidogenic effect of GOS that was 
quickly reversed when GOS consumption had ended.  In addition, the results 
indicated that the effect was dose-dependent.  Although we detected a modest 
increase of bifidobacteria numbers by cultural and qRT-PCR methods at a daily 
dose of 2.5 g of GOS, it required 5 g per day to achieve statistically significant 
higher numbers of bifidobacteria, relative to the control.  A further increase in the 
dose from 5 to 10 g of GOS did not lead to an additional increase in the absolute 
number of bifidobacteria when determined by both culture and qRT-PCR (Table 
3, Figure 1). 
Collectively, the data obtained in this study suggests that the dose does influence 
the bifidogenic effect of a prebiotic food product.  However, it has previously 
been suggested that the daily dose of a prebiotic is not a determinant of the 
prebiotic effect (Gibson et al., 2004; Roberfroid, 2007).  According to this 
argument, the prebiotic effect is influenced by the starting number of 
bifidobacteria in the subjects prior to administration of the prebiotic, such that the 
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larger the number of initial fecal bifidobacteria present in an individual, the 
greater is the potential for a bifidogenic effect.  Thus, increases in bifidobacteria, 
in absolute numbers, in response to prebiotics directly correlate with the initial 
number, but inversely correlate with log transformed increases.  Our results 
support this conclusion, as we observed that the greatest bifidogenic response to 
GOS, in absolute numbers, occurred in subjects having the highest initial 
bifidobacteria levels, while a higher log increase was observed in subjects with 
low initial numbers (Figure 2).  However, our data still clearly indicates that the 
dose of GOS was an important determinant of the prebiotic effect.  As shown 
above, when all eighteen subjects were considered, a significant bifidogenic 
effect required 5 g of GOS, relative to the control, whereas 2.5 g was not 
sufficient.  The data suggests that a minimum or ‘threshold’ dose may exist below 
which a prebiotic effect is not observed. Accordingly, in a previous study, 2.5 g of 
GOS did not lead to an increase in cell numbers of bifidobacteria (Tannock et al., 
2004).  However, our data does also indicate that there may also be a dose at 
which no additional bifidogenic effect is observed (i.e., above 5 g in our study). 
Above this threshold, the dose of a prebiotic is indeed not a determinant of the 
prebiotic effect, as suggested by Gibson and Roberfroid (Gibson et al., 2004; 
Roberfroid, 2007). We suggest, however, that the determination of a prebiotic 
dose or threshold, as determined in this study, is valuable for dietary 
recommendations, as this amount constitutes a minimum dose by which a 
significant bifidogenic effect can be achieved in a population of subjects. 
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Although all three methods of analysis showed that GOS could elicit a bifidogenic 
response when the results from the 18 subjects were pooled, we also observed 
considerable individual variations.  Thus, only 50% of the subjects showed a 
statistically significant increase of bifidobacteria following GOS consumption.  
What differentiates these responders from non-responders is unknown, but we 
suggest that one explanation may simply be due to the presence or absence of 
specific Bifidobacterium strains capable of using that prebiotic as a growth 
substrate.  Thus, responders may harbor a greater proportion of GOS-fermenting 
bifidobacteria among the gut microbiota, compared to non-responding 
individuals.  Although we did not detect differences in the initial numbers of 
bifidobacteria in responders and non-responders, individuals in the latter group 
might nonetheless lack specific GOS-utilizing strains. In addition, although the 
effective bifidogenic dose was 5 g for the subjects on average, subject-specific 
dose-response relationships were also detected (data not shown).  
In this study, we incorporated the GOS into a chewable confection product to 
simulate a relevant means of delivery.  Preliminary evaluations indicated that the 
control and GOS-containing chews were indistinguishable based on appearance, 
flavor, and chewiness.  All of the GOS dosage levels used in this study, including 
the 10 g per day dose, were well tolerated, based on the absence of any adverse 
effects compared to the control chews as reported in the symptoms diaries.  
Although subjects did report an increase in the flatulence score, significance 
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occurred between the baseline period and even the control (no GOS) treatment, 
suggesting that this outcome was due either to a placebo effect or was caused 
by another component of the chew.  Moreover, no differences in flatulence were 
reported between any of the treatment doses.  The general tolerance of GOS 
and the absence of undesirable side-effects at these dosages has previously 
been reported (Ito et al., 1990). 
Several reports have shown that DGGE is an effective method to assess the 
effect of GOS consumption on the stability and diversity of the human intestinal 
microbiota (Maukonen et al., 2008; Tannock et al., 2004).  In the latter study, the 
DNA-DGGE profiles were not altered in healthy adults following consumption of 
GOS-containing biscuits (2.5 g per day for three weeks), although changes in the 
RNA-derived DGGE profiles were observed.  The RNA-DGGE fragments whose 
intensity had increased during GOS were sequenced and subsequently assigned 
to Bifidobacterium adolescentis and/or Colinsella aerofaciens.   In the current 
study, DGGE analysis provided evidence that consumption of GOS induced 
compositional alterations in the fecal microbiota of a majority of subjects.  
Moreover, the DGGE results showed that the changes in the microbiota were 
selective, with the most consistent alteration detected being an increase in the 
intensity of a band corresponding to Bifidobacterium adolescentis. 
Although specific health benefits have not yet been causally linked to particular 
bacterial populations in the human gut, bifidobacteria are generally considered to 
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be health-promoting organisms and constitute one of the main groups of 
organisms targeted by prebiotics.  In this study, we provide evidence that a 
minimum dose of 5 g of GOS per day induced significant alterations in the gut 
microbiota in healthy human adults, mainly by increasing the number of 
bifidobacteria. We argue that dose-response studies such as the one presented 
here might enable better dietary recommendations on an effective dosage of 
prebiotics, especially when incorporated directly into foods.  However, as shown 
in this study, it appears that even when GOS is administered for many weeks 
and at high doses, there may still be some individuals for which a bifidogenic 
response does not occur. 
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Table 1. Composition (%) of chocolate chews 
Ingredient    Control Chocolate Chew  GOS Chocolate Chew  
Water       11.62     11.54 
Sugar       27.35     19.42 
GOS (Purimune)     0.00     23.40 
Corn Syrup      44.84      31.83 
Palm Kernel Oil          7.62       5.41 
Chocolate Liquor (1/2 Bakers)        7.58       7.44 
Lecithin           0.55       0.53 
Vanilla       0.44       0.43 
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Table 2. Mean ± standard deviations of weekly symptoms.  Reported on a scale of 1 (best) to 5 (worst). 
            Baseline             0.0 g                   2.5 g            5.0  g    10.0 g             Washout       
Bowel Movement     1.42 ± 0.55                1.57 ± 0.61             1.44 ± 0.55               1.39 ± 0.51           1.46 ±0.61             1.42 ± 0.79    
Stool consistency          1.56 ± 0.64                 1.63 ± 0.68             1.54 ± 0.68               1.54 ± 0.73           1.57 ± 0.65            1.50 ± 0.84  
Discomfort                     1.42 ± 0.69                 1.48 ± 0.60             1.56 ± 0.57               1.44 ± 0.65           1.52 ± 0.73            1.14 ± 0.38 
Flatulence                    1.52 ± 0.78                 1.83 ± 0.75
*
            1.85 ± 0.79
*
               1.86 ± 0.75*         2.07 ± 0.88*           1.25 ± 0.55
 
Abdominal pain             1.17 ± 0.38                 1.31 ± 0.49             1.33 ± 0.40                1.30 ± 0.50           1.30 ± 0.60            1.14 ± 0.41 
Bloating                         1.14 ± 0.33                 1.39 ± 0.75             1.43 ± 0.47                1.30 ±0.65            1.48 ± 0.90            1.08 ± 0.26 
*Significant differences detected by ANOVA (p < 0.05) between the GOS and baseline and washout treatments. 
Tukey’s post-hoc test did not detect significant differences in pair wise comparisons.          
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Table  3. Enumeration of bacterial groups through culturing  
Log 10 cfu/g feces (Mean ± SD) 
Bacterial group           Baseline           0.0 g                2.5 g               5.0 g            10.0 g                Washout 
Lactose fermenting        5.60 ± 1.14                5.68 ± 1.07        5.64 ± 0.86        5.18 ± 1.26        5.59 ± 0.85            5.78 ± 1.17      
Enterobacteria 
Enterococci             5.02 ± 0.99                 5.02 ± 1.07       4.95 ± 0.99         4.67 ± 0.93        4.70 ± 0.90           5.13 ± 1.10             
Bifidobacteria                9.32 ± 0.79                 9.48 ± 0.73       9.60 ± 0.80         9.76 ± 0.48*       9.83 ± 0.56***        9.42 ± 0.52    
Bacteroides                   9.56 ± 0.37                 9.58 ± 0.37       9.59 ± 0.35         9.47 ± 0.32        9.53 ± 0.35           9.53 ± 0.33               
Total anaerobes           10.19 ± 0.28               10.19 ± 0.20     10.11 ± 0.23       10.24 ± 0.15     10.35 ± 0.16**§§§
       
10.19 ± 0.21
 
    
 Significantly different to 0.0 g: * (p < 0.05), ** (p < 0.01), *** (p < 0.001) 
Significantly different to 2.5 g: §§§ (p < 0.001) 
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Table 4. Ratio of staining intensities of major bands as proportion of total fingerprint intensity (%) and results of sequence analysis of selected 
bands.   
Mean band intensity (± SD) 
Increasing significance 
Subject   DGGE                Baseline                    0.0 g            2.5 g          5.0 g                       10.0 g           Washout 
   fragment 
2                 C                3.68 ± 0.02             2.76 ± 0.009           4.87 ± 0.01          6.67 ± 0.03             11.89 ± 0.04**§              2.93 ± 0.02      
4       F                3.13 ± 0.02             1.23 ± 0.001           3.83 ± 0.02          3.33 ± 0.005             6.96 ± 0.02**               1.39 ± 0.002        
                   G               1.46 ± 0.007           3.94 ± 0.02             2.70 ± 0.004        5.51 ± 0.01               9.75 ± 0.03*§§               1.21 ± 0.003       
14               H               3.41 ± 0.16             6.40 ± 0.06             8.57 ± 0.02          7.41 ± 0.008             8.06 ± 0.02               0.69 ± 0.01           
15               I                 0.00 ± 0.00            0.00 ± 0.00             1.48 ± 0.002*       2.53 ± 0.01**             2.55 ± 0.002**              0.00 ± 0.00        
17               L                0.92±0.002            1.73±0.01               1.48±0.01            5.15±0.007             10.00±0.03***§§§†                          0.60±0.002 
Decreasing significance 
1     A          11.91 ± 0.03           10.73 ± 0.03            2.79 ± 0.05*         0.12 ± 0.001**           0.19 ± 0.002**           1.15 ± 0.01     
2     B                 5.07 ± 0.01             3.50 ± 0.01            3.17 ± 0.01           2.88 ± 0.003             1.03 ± 0.002             2.51 ± 0.01          
3     D                 6.51 ± 0.02            7.06 ± 0.03             3.42 ± 0.04           1.30 ± 0.02               0.001 ± 0.002           4.50 ± 0.004       
4               E                 1.88 ± 0.001          1.66 ± 0.005           3.35 ± 0.003         2.69 ± 0.02               0.35 ± 0.0009§
               
2.63 ± 0.02    
16              J                 9.74 ± 0.03            8.00 ± 0.03             7.15 ± 0.009         4.13 ± 06                  4.10 ± 0.005             4.33 ± 0.004         
17              K                8.70 ± 0.002          3.68 ± 0.04             6.79 ± 0.02            2.80 ± 0.02              0.63 ± 0.005             2.83 ± 0.004         
Significantly different to 0.0 g: * (p < 0.05), ** (p < 0.01), *** (p < 0.001)   
Significantly different to 2.5 g: § (p < 0.05), §§ (p < 0.01), §§§ (p < 0.001) 
Significantly different to 5.0 g: † (p < 0.05) 
Subjects 3, 14, 2B, 16, and 17K are included because they are   
approaching significance (p < 0.05) at 10 g compared to 0.0 g. 
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Table 5. Identification of band fragments in DGGE gels 
Subject    Band fragment     Closest related Genbank sequence (% similarity between DGGE fragment and Genbank sequence)  
1 A          Ruminococcus uncultured bacterium; 29A-b4; DQ905715 (99%) 
2 B         Lachnospiraceae uncultured bacterium; RL197_aah88b02; DQ794455 (100%) 
C          Bifidobacterium adolescentis; E-981074T; nru-5; AF275882 (100%) 
      3         D          Bacteroides uncultured bacterium; NO48; AY916250 (100%) 
       4         E         Bacteroides uniformis (T); JCM 5828T; AB050110 (100%) 
F         Bacteroides dorei (T); JCM 13471; 175; AB242142 (100%) 
      G         Bifidobacterium adolescentis; E-981074T; nru-5; AF275882 (99%) 
      14                      H          Bifidobacterium adolescentis; E-981074T; nru-5; AF275882 (100%) 
      15                      I         Bifidobacterium adolescentis; E-981074T; nru-5; AF275882 (100%) 
      16                      J         Ruminococcaceae uncultured bacterium; RL185_aan85a07;  DQ825073 (100%) 
      17                      K         Ruminococcus uncultured bacterium; B086; DQ325583 (97%) 
                                L         Bifidobacterium adolescentis; E-981074T; nru-5; AF275882 (100%) 
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Figure 1. Bifidogenic effect of GOS as determined by qRT-PCR for all eighteen 
subjects (A) and for the 9 responders (B). Significance (by ANOVA) is indicated 
at either p<0.05 (*) or p<0.001 (***).  
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Figure 2. Correlation of initial bifidobacteria levels (baseline) and the increase of 
bifidobacteria by GOS feeding (from the baseline to the average of the 5 and 10 
g dose levels) as measured by absolute numbers (A) and by log increase (B).  
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Figure 3. DGGE analysis of fecal microbiota of subjects 1, 2, 3, and 4 (A) and 
14, 15, 16, and 17 (B) by DGGE.  Bands that were significantly affected by the 
GOS treatments are outlined.  Abundance scores, as measured by DGGE band 
intensities from bands, C, G, H, I, and L, as a function of GOS doses (C).  
Correlation of Bifidobacterium adolescentis band intensities from subjects 2, 4, 
14, 15, and 17 for all time points to cell numbers, as measured by 
Bifidobacterium genus-specific qRT-PCR (D). 
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ABSTRACT  
The goal of this research was to gain a community wide perspective of the 
impact of GOS on the fecal microbiota of healthy human subjects using high 
throughput multiplex community sequencing of 16S rRNA tags.  Eighteen healthy 
human subjects consumed GOS containing caramel-like confectionary products 
for twelve weeks, with four increasing dosages of GOS.  Multiplex sequencing of 
the 16s rRNA tags revealed that GOS induced significant compositional 
alteration in the fecal microbial populations by increasing the phyla 
Actinobacteria.  At the species level, the changes evoked by GOS resulted in 
increases of six of the Bifidobacterium species, including B. adolescentis, B. 
longum, and B. catenulatum.   The population shifts caused by consumption of 
10 g of GOS were numerically substantial, leading for example, to a ten-fold 
increase in bifidobacteria in four subjects, enriching them to 18-33% off the fecal 
microbial community, and a five-fold increase in seven additional subjects.  
Moreover, this increase in bifidobacteria abundance, to greater than 20% in 
some individuals, was generally at the expense of only one group of bacteria, 
namely the genus Bacteroides. The responses to GOS and their magnitudes 
varied between individuals, and they were reversible and tightly associated with 
the increasing dosage of GOS.  Our results demonstrate that GOS is remarkable 
for its ability to enrich specifically for bifidobacteria in human fecal samples, 
although it is utilized by a wide variety of bacterial inhabitants of the intestinal 
tract when studied in vitro. 
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INTRODUCTION 
It has become increasingly recognized that the gastrointestinal microbiota 
plays a critical role in human health (13).  The composition and activity of this 
microbiota affect nutrient utilization and adsorption, the development and 
maturation of the immune system, and resistance to infections (24, 43, 47).  
Aberrations in the gut microbiota have been linked several complex diseases, 
including inflammatory bowel disease (13, 19, 34), colitis (27, 33), osteoporosis 
(1,35), obesity, atherosclerosis and cardiovascular disease (32, 44, 14), type 2 
diabetes (9), colorectal cancer (21, 55,20), arthritis, and allergic diseases (26, 30, 
31, 42, 59).  Moreover, the discovery that it is possible to effect changes in the 
intestinal microbiota by relatively small dietary modifications (35) has led to the 
suggestion that these aberrations or imbalances can be corrected and host 
health improved (22). 
One strategy by which to modulate composition and metabolism of the 
intestinal microbiota are prebiotics.  Prebiotics are defined as “a selectively 
fermented ingredient that allows specific changes, both in the composition and/or 
activity in the gastrointestinal microbiota that confers benefits upon host well-
being and health” (45).  Several of these carbohydrates are used commercially in 
foods, including inulin, fructooligosaccharides (FOS), resistant starch, and 
galactooligosaccharides (GOS).  There is now convincing in vivo evidence 
showing that prebiotics can promote growth of bifidobacteria in the intestinal tract 
of infants and adults (56).  For GOS in particular, 2 to 3 log increases in the 
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number of bifidobacteria have been reported (15). However, the human gut 
microbiota is composed of hundreds of species (22), and the impact of prebiotics 
on other members of the intestinal microbiota and the community structure in 
general is less well understood.  
.  The specificity of prebiotic substrates was initially attributed to their 
selective fermentation in the intestinal tract. Several surveys have revealed that 
several species of Bifidobacterium, as well as Lactobacillus, are able to ferment 
prebiotic substrates.    Interestingly, however, in monoculture, several colonic 
bacteria other than bifidobacteria have been reported to utilize prebiotics as an 
energy or carbon source, including species of Clostridium, Enterococcus, 
Bacteroides, and Escherichia.  These groups of bacteria have previously not 
been reported to be enriched through prebiotics in human trials, and other 
mechanisms have been proposed for the relatively specific bifidogenic effect of 
prebiotics, such as tolerance to SCFA and acidification and the ability to adhere 
to prebiotic substrates (12). However, most studies on the in vivo specificity of 
prebiotics applied methodologies with limitations in their ability to address the 
question on how specific prebiotics are. These studies relied on either cultural 
enumeration methods that fail to detect the majority of microbial species present 
in the human gut (2, 8, 16, 29), or they used molecular methods that are 
restricted by focusing on selected bacterial groups (qRT-PCR, fluorescent in situ 
hybridization (FISH;16) or suffer from a small dynamic range (DGGE; 52,15, T-
RFLP). Several of these studies showed that the prebiotic response was not 
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completely restricted to bifidobacteria. For example, Tannock and co-workers 
showed that FOS increased staining intensities of bands corresponding to 
Bifidobacterium adolescentis and Colinsella aerofaciens (52). In a study in mice, 
Apajalahti and colleagues found that Inulin induced community shifts that 
included increases of bifidobacteria and a decrease in clostridia, but the major 
changes were observed within previously unknown taxa (3). Therefore, although 
the bifidogenic effect of most prebiotic carbohydrates is clearly established, the 
exact effect of prebiotics on the entire community composition and structure 
remains an important field of study.  Massively parallel sequencing of amplified 
16s DNA tags via pyrosequencing now provides the means to quantify the fecal 
microbiota at increased depth spanning the entire microbial community at very 
high sensitivities.  Thus, a much more detailed analysis of how prebiotics affect 
the microbiota can be achieved, and community wide shifts in throughout the 
entire phylogenetic spectrum of the bacterial population can be measured. 
We recently reported that GOS, incorporated into caramel-like 
confections, increased the amount of bifidobacteria in 9 out of 18 healthy adults 
at doses above 5 g per day as assessed by specific culture, qRT-PCR, and 
DGGE (15).   Only one other bacterial group, Bacteroides dorei, was detected by 
DGGE to become increased in one single subject, suggesting that GOS was 
highly specific in its stimulation of bifidobacteria. However, techniques used in 
our previous study were restricted in both depth and breadth, and the goal of this 
current study was to gain an in depth perspective of the impact of GOS in these 
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subjects using high throughput multiplex community sequencing of 16S rRNA 
tags.  We discovered that GOS was remarkable for its ability to enrich specifically 
for bifidobacteria in human fecal samples, although it is utilized by a wide variety 
of bacterial inhabitants of the intestinal tract in vitro. . 
 
MATERIALS AND METHODS 
Experimental design. The details for how this study was conducted were 
previously described in detail (15). Briefly, caramel chews were administered to 
18 healthy human volunteer during a 16 week period.  The first two weeks were 
established as the baseline period (no chews administered), and this was 
followed by four sequential testing periods during which chews were 
administered for three weeks with GOS dosages at levels of 0.0 g, 2.5 g, 5.0 g, 
and 10.0 g GOS per day.  A final two-week washout period (no chews) was 
performed at the end of the fourth testing period (weeks 15 – 16).  The study was 
approved by the Institutional Review Board of the University of Nebraska. 
 Molecular characterization of the fecal microbial communities by 
pyrosequencing of 16S rRNA tags. Fecal samples were collected weekly and 
processed as described previously (15). Pyrosequencing of 16S rRNA tags was 
preformed from fecal DNA as described by Martínez et. al (2010). Briefly, the V1-
V3 region of the 16S rRNA gene was amplified by PCR from fecal DNA using 
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primers were modified to work with the Roche-454 Titanium kit.  A mixture (4:1) 
of the primers B-8FM 
 (5’-
CCTATCCCCTGTGTGCCTTGGCAGTCTCAGAGAGTTTGATCMTGGCTCAG-
3’) 
 and B-8FMBifido 
 (5’-
CCTATCCCCTGTGTGCCTTGGCAGTCTCAGAGGGTTCGATTCTGGCTCAG-
3’), 
were used as the forward primers.  The primer A518R 
 (5’-
CCATCTCATCCCTGCGTGTCTCCGACTCAGBBBBBBBBATTACCGCGGCTG
CTGG-3’) containing an 8-base barcode sequence was used as the reverse 
primer.  Sequences were then assigned to their respective samples via the 
barcode.  The 8FMBifido was used in combination with primer 8FM as 16s DNA 
sequences within the genus Bifidobacterium are not well amplified by the latter 
primer (37).   
Equal amounts of the PCR products were combined, gel purified, and 
sequencing was performed by the Core for Applied Genomics and Ecology 
(CAGE, University of Nebraska-Lincoln)  with the 454/Roche A sequencing 
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primer kit using a Roche Genome Sequencer GS-FLX.  Using the Ribosomal 
Database Project (RDP) Pyrosequencing Pipeline (http://pyro.cme.msu.edu/) 
‘Initial Process’ tool, sequences were binned according to the barcode (11).  
Default parameters were used to remove sequences containing any ambiguous 
nucleotides, except for the minimum sequences length, which was set to 300 bp.  
BioEdit Software was used to trim the quality approved sequences to 450 bp 
before their submission to the sequence analyses (see below).   
Sequence analyses to characterize microbial populations. Sequences 
obtained with pyrosequencing were analyzed using two independent 
approaches, a taxonomy dependent and a taxonomy independent.  First, the 
Classifier tool of the RDP was applied (with a minimum bootstrap value of 80%) 
to obtain a taxonomic assignment of all sequences.  The Classifier approach 
allowed a fast determination of the proportions of bacterial groups at different 
taxonomic levels (phylum, family, and genus).   Second, sequences were 
assigned to Operational Taxonomic Units (OTUs).  For this, all sequences from 
each subject were individually aligned using the RDP Aligner web tool, and then 
clustered using the RDP Complete Linkage Clustering web tool (with a maximum 
distance cutoff of 97%; 11). The OTU picking was done on a per subject base as 
the entire data from all subjects contained too many sequences for a quality 
alignment.  Excluded from the analyses were OTUs that contained less than 
three sequences.  Using Statistical Analysis Software (SAS) to perform ANOVA, 
the OTUs that were significantly affected by the dietary treatments in each 
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subject were identified.   Representative sequences from each OTU whose 
abundance was significantly influenced by GOS were subjected to taxonomic 
classification using SeqMatch, an RDP web tool.  From each statistically 
significant OTU identified, five random representative sequences were aligned to 
form consensus sequences using SeqMan Software.    The consensus 
sequences were grouped and aligned according to phylum (Actinobacteria, 
Bacteroidetes, Firmicutes, Fusobacteria, Proteobacteria, and Verrucomicrobia) 
together with the most closely related type strains or entry in the NCBI database 
using Muscle 3.6 (18).   Phylogenetic trees were built by neighbor-joining with 
1,000 bootstrap replicates with MEGA 4.0 Software (53).  Using visual analyses 
and a distance matrix, OTUs were assigned as sequence clusters with >97% 
identity.   Quantification of the OUT in each subject was performed by BLASTn 
analysis. For this, consensus sequences were generated for each of the OTU 
sequence clusters as described previously.  A local nucleotide database was 
established through a PERL script, which combined all eighteen subjects’ 
sequences, detected by pyrosequencing, into one database.  A BLASTn 
algorithm was used with a 97% cutoff (min. length 300 bp) to quantify each OTU 
in the fecal bacterial populations within each sample.  Samples that were closely 
related to Bifidobacterium adolescentis were re-analyzed with a BLASTn 
algorithm at a cutoff of 98% (min. length 300 bp) as clearly differentiated clusters 
could be identified that showed overlap with 97% algorism.  The quantification of 
OTUs in all subjects was verified to ensure that individual sequences were not 
100 
 
being assigned to different OTUs.  In three occasions, seven OTUs that were 
initially identified as distinct had very high shared sequence similarities, and were 
thus merged together into three OTUs.   
Determination of community diversity. Two different methods, the 
generation of rarefaction curves and Shannon’s index, were applied to determine 
the diversity of the fecal microbiota using 16S rRNA sequence data.  The DNA 
sequences of each sample were individually aligned and clustered using RDP 
web tools Aligner and Complete Linkage Clustering.  Individual cluster files 
corresponding to each fecal sample were used to construct Rarefaction curves 
and determine the Shannon’s Index.   
Statistical analysis. To identify differences in fecal microbiota 
composition induced through dietary treatments (0.0 g, 2.5 g, 5.0 g, and 10.0 g 
GOS) in all eighteen subjects, one-way ANOVA tests with repeats were 
performed.  Samples obtained during the baseline and washout periods were not 
included within the statistical analysis.  Post hoc pair-wise comparisons were 
done using Tukey’s method.  P-values of < 0.05 were considered significant 
unless otherwise stated.   
In vitro Fermentation of GOS by colonic bacteria.  A total of twenty-two 
anaerobic bacteria which were mainly of intestinal origin were screened for their 
ability to use GOS as a growth substrate.  Included were Clostridium butyricum 
23588, Clostridium bifermentans 23591, Clostridium difficle 23596, Clostridium 
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innoccuum 23601, Clostridium paraputrificum 23600, Clostridium perfringes 
23962, Clostridium perfringes 23508, Clostridium ramosum 23617, Clostridium 
rumen 23494, Clostridium sporogenes 23598, Clostridium histolyticum 
19401,Enterococcus faecium 2354, Enterococcus faecalis 537, Enterobacter 
aerogenes 407, Enterobacter aerogenes 410, and Streptococcus salivarius 3714, 
Bacteroides thetaiotaomicron 5482, Bacteroides distasonis V923, Bacteroides 
fragilis 43858, Bacteroides uniformis BU1100, Bacteroides fragilis 638, and 
Bacteroides ovatus V975.  Bacteria were initially propagated in Brain Heart 
Infusion (BHI)  or  Reinforced Clostridial Agar (RCA), and were transferred (2%) 
into a basal medium containing 5 g/L Peptone No 3 (Becton, Dickinson, and 
Company), 5.0 g/L Casitone (Becton, Dickinson, and Company), 0.5 g/L L-
Cysteine (Sigma), 40 mL Salt Solution, 10 mL Hemin (Sigma), 900  µL Vitamin 
K3 (Sigma), and 1 g/L Yeast Extract (Becton, Dickinson, and Company).  In 
addition, cells were also inoculated into basal medium containing either 1% 
glucose or 1% GOS.  All cultures were incubated at 37˚C in an anaerobic 
chamber (Forma Scientific, Mareitta, Ohio) containing an atmosphere of 85% 
Nitrogen, 10% Hydrogen, and 5% Carbon dioxide and assessed for growth by 
optical density measurement at 600nm in a Beckman Model 640 
spectrophotometer.  Each experiment was replicated in triplicate and the average 
optical densities were determined. 
RESULTS 
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  The effect of GOS on the fecal microbial community in human 
subjects.  A total of 288 fecal samples were sequenced by pyrosequencing, and 
2.3 million sequences were obtained, with an average of 8,200 sequences per 
sample (after quality control analysis).  The mean sequence length was 
approximately 450 bp.  Subsequent identification of operational taxonomic units 
(OTUs) among the samples revealed an average of 2,022 OTUs per subject.  To 
assess the effect of GOS on diversity of the fecal microbiota during the baseline, 
treatment, and washout periods, rarefaction curves for all eighteen subjects were 
generated (Figure S1).  Rarefaction analyses, however, revealed that 
consumption of GOS did not cause significant alterations in the bacterial diversity 
of the fecal samples (p < 0.0713). 
During the baseline period, the composition of the microbiota among the 
eighteen subjects was dominated by the phyla Firmicutes (64%) and 
Bacteroidetes (28%).  Other phyla detected included Actinobacteria (3%), 
Verrucomicrobia (1%), and Proteobacteria (1%).  Approximately 3% of the 
sequences remained unclassified.  At the family level, the predominant groups 
were the Lachnospiraceae (31%), Ruminococcaceae (18%), Bacteroidaceae 
(12%), and Bifidobacteriaceae (5%).  The most common genera included 
Bacteroides (12.2%), Fecalibacterium (7.7%), Blautia (7.4%), Ruminococcus 
(3.7%), Roseburia (2.2%), Bifidobacterium (1.5%), and Dorea (1.3%). 
 Sequence proportions determined by pyrosequencing were used to 
determine the effect of GOS on the composition of the gastrointestinal microbiota 
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among all 18 subjects.  The groups that were significantly affected are shown in 
Table 1, according to phylum, family, genus (by RDP Classifier), and species (as 
OTUs).  The control chew (no GOS) had no effect on the fecal microbiota, as the 
microbial populations during this period were the same as during the baseline 
and washout.  In addition, a dose of 2.5 gram of did not induce any detectable 
changes within the fecal microbiota.   In contrast, consumption of 5.0 g GOS led 
to a significant increase (p < 0.05) of bifidobacteria at both the family and genus 
level, compared to the control dose.   At the species level, the abundance of only 
one OTU that accounted for the species , Fecalibacterium prausnitzii, increased 
significantly at this dose.   A significant decrease in abundance was also 
observed for both the family and genus level for Bacteroidaceae (p < 0.01) and 
Bacteroides (p <0.01), respectively, at the 5.0 g dose compared to the control. 
At the 10.0 g GOS dose, taxonomy-based analysis (using Classifier) 
revealed differences in the proportions of several phyla.  There was a significant 
increase in Actinobacteria compared to the control (p < 0.001), as well as 
compared to the 2.5 g dose (p < 0.05).  This change was associated with an 
increase both in the family Bifidobacteriaceae and in the genus Bifidobacterium.  
The BLASTn analysis revealed that eight of the OTUs showed statistically 
significant differences as the GOS doses increased, with five of the OTUs being 
linked to known bacterial species.   A significant increase was observed after the 
10.0 g dose with six OTUs that account for Bifidobacterium species  (Table 1). 
Three of these OTUs account for the described species Bifidobacterium 
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adolescentis, B. longum, and B. catenulatum, while three showed <97% identity 
to the closest type strain (Table 1, Figure 1).  Interestingly, two of OTUs that did 
not account to any described Bifidobacterium species (Bifidobacterium spp II (p < 
0.05), Bifidobacterium spp III), showed the numerically highest response to GOS 
(Table 1).  
There were a very small number of bacterial taxa other than bifidobacteria 
that were influenced by GOS. Significant decreases were observed only within 
the family Bacteroidaceae (p < 0.05) and the genus Bacteroides (p < 0.05) when 
compared to the control dose of GOS. The OTU-based approach identified two 
additional taxa that differed significantly, including  Coprococcus comes (p < 
0.05), and Fecalibacterium prausnitzii (p < 0.05), both of which decreased after 
10.0 g of GOS when compared to the control and 5.0 g, respectively.  However, 
a significant increase in Fecalibacterium prausnitzii (p < 0.05) was observed after 
a dose of 5.0 g of GOS compared to the control (Table 1). There were also 
significant decreases that were observed within two species groups, 
Fecalibacterium prausnitzii (p < 0.05) when compared to the 5.0 g dose, and 
Coprococcus comes (p < 0.05) when compared to the control dose.  
Consumption of GOS induced population shifts that were substantial 
but varied between subjects.  The consumption of GOS at higher levels, 5.0 g 
and especially 10.0 g, resulted in major compositional shifts within the 
gastrointestinal microbiota of a subset of subjects.  The most substantial 
alterations, numerically, were the changes observed in the abundances of the 
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genus Bifidobacterium, that increased approximately 10 fold (from 1 - 4% to 18 - 
33%) in four subjects, and an about 5 fold in seven additional subjects.  In 
contrast, there was a  a decrease in the abundance of Bacteroides in 17 subjects 
after the 5.0 g GOS dose, with 14 of those subjects having a further decrease 
after consumption of 10.0 g of GOS.  The findings clearly showed that despite 
these substantial overall population shifts, the effect of GOS on the intestinal 
composition of subjects was still subject to considerable variation among 
individuals (Figure 2).  The data revealed that there were some individuals that 
were essentially unaffected by GOS consumption, whereas other experienced 
several significant changes.  The most consistent alteration detected by this 
analysisod was the reduction in the Bacteroidetes (at the family, genus, and 
species levels), which occurred within all of the subjects at some point after 5.0 g 
of GOS was consumed (Figure 2).  Other common alterations were the increase 
in the Actinobacteria (at the phylum, family, genus, and species levels) which 
was observed in sixteen of the eighteen subjects after 5.0 g and seventeen of the 
subjects after 10.0 g of GOS.   
Temporal dynamics of microbial populations in response to GOS.  
Analyses of the community profiles provided insight into how GOS influenced the 
population dynamics over the entire 16 week study period.  All of the changes 
induced by GOS were reversible within one week, and no differences (Student’s 
t-test, p > 0.05) could be detected in the proportions of the bacterial groups 
between the first washout sample and the baseline sample (Figure 3).   The 
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temporal patterns of the three main phylum (Actinobacteria, Bacteroidetes, and 
Firmicutes) and two of the selected genera (Bifidobacterium and Bacteroides) for 
five representative subjects showed that these groups were stable in their 
temporal response to GOS.  For example, levels of Actinobacteria, 
Bacteroidetes, and Firmicutes were remarkably stable in fecal samples at the 
baseline and washout periods, and their populations returned to the baseline 
level within one to two weeks after GOS consumption was stopped.  The same 
observations were also made at the genus level for Bifidobacterium and 
Bacteroides.  These taxa were significantly affected by consumption of GOS, as 
population dynamics were very similar throughout, indicating that these bacterial 
groups might be specifically targeted 
In vitro growth of gastrointestinal microbiota cultures on the 
prebiotic GOS.  The growth of twenty-two strains of bacteria, most of which 
originated from the human intestinal tract, in media containing GOS was 
compared with growth in media containing glucose (positive control; data not 
shown) or without an additional source of carbohydrate.  In general, 6 of the 11 
Clostridium strains could utilize GOS (Figure S3A) indicated by a higher final OD 
when compared to growth without carbohydrates, and in addition, three of the six 
strains of Bacteroides also grew well on GOS. Growth on GOS was not 
observed, however, for Enterococcus, Enterobacter, or the species included 
within the genus Enterococcus and Streptococcus did not result in significantly 
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different high levels of fermentation on GOS, when compared to the control (no 
GOS). 
 
DISCUSSION 
  We recently reported that consumption of GOS induced bifidogenic shifts 
in the fecal microbial community of 18 healthy human adults (15).  Daily doses of 
5.0 g were generally necessary before these effects could be observed either by 
cultural methods, DGGE, and  qRT-PCR.  The results were consistent with 
several other studies involving human subjects consuming GOS at similar doses 
(7, 8, 16, 58).  In addition, we also observed that when the fecal samples from 
each subject were analyzed individually, the bifidogenic response to GOS 
occurred consistently in only half of the subjects, whereas the others were 
consistent “non-responders” (15).   However, because of the relatively low 
resolution of DGGE and the Bifidobacterium-specific primers used in qRT-PCR, 
we were unable to detect other changes in the microbiota that occurred as a 
result of GOS consumption.  Therefore, all 288 samples (18 subjects at 16 
weekly time points) from the previous study were used in pyrosequencing 
reactions to obtain individual community profiles.  Our findings were entirely 
consistent with our previous report, but also revealed important insights 
regarding how GOS influences the intestinal microbiota. 
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Prebiotics are described, by definition, as being “selectively fermented” 
and able to induce changes in the gastrointestinal microbiota that are “specific” 
(45).  Previous methods have been effective in assessing the effect of GOS 
consumption on the stability and diversity of the human intestinal microbiota (15, 
39, 52); however, the inability to quantify the prebiotic effect beyond the major 
taxa has made it difficult to test this definition and to assess the effect of 
prebiotics at greater resolution.  Results from high throughput pyrosequencing 
has now allowed an in depth analysis of the microbial community as a whole and 
has shown for the first time that GOS induces changes that are remarkably 
selective.  Indeed, the only bacteria that consistently increased in abundance in 
response to GOS feeding were bifidobacteria.  Moreover, this increase in 
bifidobacteria abundance, to greater than 20% in some individuals, was generally 
at the expense of only one group of bacteria, namely the genus Bacteroides.  
Although abundance of Bifidobacterium increased in some individuals without a 
commensurate decrease in Bacteroides (and vice versa), in general, 
bifidobacteria increased and bacteroides decreased (Table 1, Figure 2) during 
GOS consumption.  This data clearly shows that GOS, as a prebiotic, is highly 
specific toward the Actinobacteria phylum, in particular bifidobacteria (Figure 1B). 
In this study, we observed not only changes at phylum, family, and genus 
level, but perhaps more importantly, also at the species level (Figure 2A and B).  
The most consistent response, at the 10.0 g treatment, was an increase of 
Bifidobacterium adolescentis that was detected in eight out of the eighteen 
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subjects.  Interestingly, this was the same species that we previously identified 
from DGGE analyses and that Tannock et al. (2004) also detected in response to 
GOS consumption.  Although Bifidobacterium are generally associated with 
humans and animals, B. adolescentis, in particular, is common in children and 
dominant in adults (4, 5, 6, 40).  The abundance of two other Bifidobacterium 
species also increased at the 10 g GOS dose, Bifidobacterium longum and 
Bifidobacterium catenulatum, as well as three unidentifiable Bifidobacterium spp 
(Table 1; Figure 1A and B).  This data suggests that while GOS is highly specific 
toward the genus Bifidobacterium, the ability to ferment GOS appears to extend 
to only a few species. 
As we noted previously, the response to GOS consumption is subject to 
considerable individual variation (38), an observation confirmed by the 
pyrosequencing data.  Of the 54 OTUs that were identified in individual subjects, 
46 did not reach significance when all of the subjects were included in the 
analysis.  In addition, none of the taxa that were significantly affected by GOS 
showed a response in all eighteen subjects.  Of the eight OTUs that were 
identified as significant, only two were closely identified with B.adolescentis.  Due 
to the high percentage of shared sequences, these two OTUs were re-analyzed 
with a 98% similarity score, as well as a chimera test.  They were subsequently 
classified as separate OTUs, confirming that this species was most commonly 
increased (seen in eight subjects) with consumption of GOS (Figure 1A). 
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The highly individual response to GOS may occur for one of several 
possible reasons.  First, the presence or absence of specific strains, capable of 
metabolizing GOS, would appear to be the major determinant, as few OTUs are 
completely conserved among humans (54, 57).  Thus, the presence of specific 
GOS-metabolizing strains would confer responder status on that individual, other 
individuals in which GOS strains are absent would be non-responders.  Other 
factors could also account for these results, including host specific environmental 
constrains that would restrict the ability of the bacterial group to increase in 
numbers even if a suitable substrate is provided (38).  In addition, host digestive 
enzymes may be secreted that affect the amount of GOS that withstands 
digestion. 
 The ability of GOS to support growth of a range of colonic bacteria, as we 
observed in this study (Figure S3A), would appear to be inconsistent with the 
very definition of a prebiotic.  The ability of species of Clostridium, Bacteroides 
and Streptococcus to utilize GOS in pure culture, has previously been reported, 
as well Rycroft et al. (2001).  Clearly, however, the substrate preferences and 
competitive forces that exist in the gastrointestinal environment are quite different 
from pure monoculture environments.  Although the abundance of Actinobacteria 
was much lower than Firmicutes or Bacteroides during baseline and control 
periods, only the former group was stimulated by GOS, despite the apparent 
ability of the latter groups to grow on GOS.  Thus, it would appear that a 
competitive environment is necessary to demonstrate a prebiotic effect. 
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B ase line 0 .0  g 2 .5  g 5 .0  g 10 .0  g W ashout P  va lue
A ctinobacte ria 2 .52  ± 2 .34 2 .58  ± 3 .59 3 .69  ± 4 .33 5 .39  ± 6 .11 7 .19  ± 8 .88 ***§ 2 .09  ± 2 .51 < 0 .0001
B ifidobacte riaceae 1 .87  ± 2 .28 2 .03  ± 3 .59 2 .99  ± 3 .72 5 .11  ± 5 .77 * 7 .36  ± 8 .68***§§ 1 .49  ± 2 .36 < 0 .0001B acte ro idaceae 12 .22  ± 7 .43 15 .03  ± 10 .66 13 .29  ± 9 .24 11 .20  ± 9 .11 ** 11 .66  ± 9 .22 * 13 .69  ± 8 .27 0 .003
Bifidobacterium 1 .54  ± 1 .95 1 .68  ± 2 .97 2 .55  ± 3 .25 4 .32  ± 5 .03 * 6 .24  ± 7 .71 ***§§ 1 .26  ± 2 .04 < 0 .0001
Bacteroides 12 .22  ± 7 .43 15 .03  ± 10 .66 13 .29  ± 9 .24 11 .20  ± 9 .11 ** 11 .66  ± 9 .22 * 13 .69  ± 8 .27 < 0 .0001
B. adolescentis 0 .37  ± 0 .56 0 .34  ± 0 .89 0 .46  ± 0 .86 0 .85  ± 1 .09 1 .03  ± 1 .55 * 0 .21  ± 0 .48 0 .0101
Bifidobacterium spp I 0 .15  ± 0 .36 0 .18  ± 0 .33 0 .25  ± 0 .55 0 .52  ± 1 .13 0 .77  ± 1 .41 *§ 0 .12  ± 0 .25 < 0 .0001
Bifidobacterium spp II 0 .46  ± 0 .94 0 .60  ± 1 .53 0 .76  ± 1 .72 1 .41  ± 2 .38 2 .00  ± 3 .45 *§ 0 .22  ± 0 .45 < 0 .0001
Bifidobacterium spp. III 0 .62  ± 1 .21 0 .78  ± 2 .19 0 .98  ± 2 .02 1 .82  ± 3 .30 2 .50  ± 4 .55 *§ 0 .40  ± 0 .92 0 .0088
B. longum 0 .09  ± 0 .23 0 .09  ± 0 .23 0 .12  ± 0 .32 0 .22  ± 0 .50 0 .33  ± 0 .85 * 0 .15  ± 0 .38 0 .0232
B. catenulatum 0 .15  ± 0 .34 0 .27  ± 0 .88 0 .56  ± 1 .38 0 .51  ± 1 .16 0 .91  ± 2 .08 ** 0 .28  ± 0 .78 0 .0105
F. prausnitzii 3 .52  ± 2 .71 3 .21  ± 2 .26 3 .71  ± 2 .67 4 .37  ± 3 .67 * 3 .16  ± 1 .82 † 3 .42  ± 2 .28 < 0 .0001
Coprococcus comes 2 .90  ± 2 .04  2 .40  ± 1 .75  2 .12  ± 1 .24 1 .99  ± 1 .55 1 .78  ± 1 .11 * 2 .15  ± 1 .30 < 0 .0001
Phylum
Family
Genus
Species (OTUs)
Table 1.  Abundance of bacterial taxa that were impacted by GOS consumption in fecal samples of eighteen human
subjects as determined by pyrosequencing of 16S rRNA tags. 
Proportion of bacterial taxa expressed in percentage (Mean ± SD)
1 12 2 2 2 3
Bacteria populations are averages of the two time points of the baseline period and the two time points of the washout
period.
Bacteria populations are averages of all three time points of the feeding periods
Bacterial populations during the dietary treatments were compared to eachother with repeated measures ANOVA
and Tukey’s post hoc test
1
2
3
Significantly different to 0.0 g: *(p < 0.05), **(p < 0.01), ***(p < 0.001)
Significantly different to 2.5 g: §(p < 0.05), §§(p < 0.01)
Significantly different to 5.0 g: †( p < 0.05)
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 Figure 1. Characterization of the fecal microbiota in eighteen subjects that 
consumed increasing doses of GOS by multiplex pyrosequencing of 16S rRNA 
tags. A phylogenetic tree that encompasses the phylum (A) Actinobacteria is 
shown. The tree contains representative sequences of all OTUs detected to be 
impacted by GOS in individual subjects together with sequences of related 
entries in the database (which included both type strains of known species and 
sequences from molecular studies of human fecal samples). Sequences were 
aligned in Muscle 3.6 and the trees were built using the neighbor-joining 
algorithm with 1,000 bootstrap replicates in MEGA 4.0. Open black and closed 
black symbols were used to label sequences from individual subjects. OTUs that 
were not significantly affected in all eighteen subjects were labeled as ‘No 
significance.’ The graphs next to the trees show the abundance of OTUs and 
bacterial groups that were significantly altered during the dosages (0.0 g, 2.5 g, 
5.0 g, and 10.0 g). A graph (B) that incorporates all of the Bifidobacterium 
species altered during consumption of GOS, for all eighteen subjects, is also 
shown. These graphs show mean proportions of the three individual samples 
taken during the treatment periods for each subject. Baseline and washout refer 
to samples taken in periods where no GOS was consumed. Repeated measures 
ANOVA in combination with a Tukey’s post-hoc test were performed to indentify 
differences between treatment groups, and the baseline/washout periods were 
not included in the statistic analysis. (*p < 0.05, **p < 0.01, ***p < 0.001). 
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Figure 2. Bubble plots showing differences in the proportions of bacterial taxa as 
a percentage of the whole bacteria population detected during consumption of 
5.0 g (A) and 10.0 g (B) when compared to the control period. The size of the 
bubbles is representative of the percent difference. Black ovals represent 
increases in proportions induced through GOS consumption, and white ovals 
represent a decrease. 
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 Figure 3. Temporal dynamics of the human fecal microbiota in response to the 
consumption of increasing doses of GOS shown in five human subjects. Graphs 
on the left show proportions of the three main phyla and two genera 
(Bifidobacterium and Bacteroides) altered for subjects considered ‘responders’, 
which graphs on the right show proportions of the same three main phyla and 
two genera altered for subjects considered ‘non-responders’. 
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Figure S1. Diversity of species richness of the fecal microbiota in eighteen 
human subjects that consumed doses of 0.0 g, 2.5 g, 5.0 g, and 10.0 g of GOS. 
Rarefaction curves showing the amount of OTUs in all individual fecal samples 
taken from eighteen subjects. 
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Figure S2. Characterization of the fecal microbiota in eighteen subjects that 
consumed increasing doses of GOS by multiplex pyrosequencing of 16S rRNA 
tags. Phylogenetic trees that encompass the phyla (A) Firmicutes and (B) 
Bacteroidetes are shown. The trees contain representative sequences of all 
OTUs detected to be impacted by GOS in individual subjects together with 
sequences of related entries in the database (which included both type strains of 
known species and sequences from molecular studies of human fecal samples). 
Sequences were aligned in Muscle 3.6 and the trees were built using the 
neighbor-joining algorithm with 1,000 bootstrap replicates in MEGA 4.0. Open 
black and closed black symbols were used to label sequences from individual 
subjects. OTUs that were not significantly affected in all eighteen subjects were 
labeled as ‘No significance.’ Arrows to the right of each cluster indicate the 
number of subjects that showed statistical significance after ANOVA analysis. 
The direction of the arrow indicates either a significant increase (↑) or significant 
decrease (↓) for each subject showing significance for that particular OTU 
cluster. 
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Figure S3. Twenty-two anaerobic bacteria of human gastrointestinal origin were 
screened in vitro to determine their ability to utilize GOS. Optical density for each 
of the strains is shown (A), with significant differences determined by students T-
test and indicated by (* p < 0.05). Each of the strains used in the study (B) were 
obtained from the USDA. 
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In this research, we established that consumption of the prebiotic GOS 
induced changes on the composition of the human gastrointestinal microbiota.  
Evidence for this conclusion was exhibited using both cultural and molecular 
methods to enumerate and characterize the shift in selected bacterial 
populations.  Specifically, selective plating methods were used to enumerate 
bifidobacteria, Bacteroides, enterobacteria, Enterococci, lactobacilli, and total 
anaerobes.  Culture-independent methods included denaturing gradient gel 
electrophoresis (DGGE), quantitative real-time PCR (qRT-PCR), and high 
throughput multiplex community sequencing of 16S rRNA tags.  We 
hypothesized that after a particular dosage level of GOS, a bifidogenic response 
would occur.  Also, we anticipated that GOS would have a community wide affect 
outside of the known bifidobacteria population.  Described below are the major 
findings of this research. 
 A dose response relationship necessary to elicit a bifidogenic effect in a 
majority of subjects was seen after a 5 g dose of high purity GOS. 
 Even when GOS was administered for many weeks and at high doses, 
there were still some individuals for whom a bifidogenic response did not 
occur; this results supports the concept that some individuals are 
responders whereas other are non-responders. 
 The population shifts caused by consumption of 10 g of GOS were 
numerically substantial, leading to a ten-fold increase in bifidobacteria in 
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four subjects, enriching them to 18-33% off the fecal microbial community, 
and a five-fold increase in seven additional subjects. 
 The increase in bifidobacteria abundance was generally at the expense of 
only one group of bacteria, namely the genus Bacteroides.   
 GOS is utilized by a wide variety of bacterial inhabitants of the intestinal 
tract when studied in vitro, but is remarkable for its ability to enrich very 
specifically for bifidobacteria in vivo. 
 
 
